WO2023100152A1 - Glutathione compositions and methods of use - Google Patents
Glutathione compositions and methods of use Download PDFInfo
- Publication number
- WO2023100152A1 WO2023100152A1 PCT/IB2022/061725 IB2022061725W WO2023100152A1 WO 2023100152 A1 WO2023100152 A1 WO 2023100152A1 IB 2022061725 W IB2022061725 W IB 2022061725W WO 2023100152 A1 WO2023100152 A1 WO 2023100152A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- formulation
- oil
- compositions
- liposomes
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 234
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title claims abstract description 130
- 229960003180 glutathione Drugs 0.000 title claims abstract description 64
- 238000000034 method Methods 0.000 title claims abstract description 56
- 108010024636 Glutathione Proteins 0.000 title claims abstract description 43
- 238000009472 formulation Methods 0.000 claims abstract description 83
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 claims abstract description 79
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 52
- 102000008133 Iron-Binding Proteins Human genes 0.000 claims abstract description 44
- 108010035210 Iron-Binding Proteins Proteins 0.000 claims abstract description 44
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 39
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 39
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims abstract description 36
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 28
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 10
- 239000002502 liposome Substances 0.000 claims description 68
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 47
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 47
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 46
- 235000014121 butter Nutrition 0.000 claims description 37
- 239000003921 oil Substances 0.000 claims description 28
- 235000019198 oils Nutrition 0.000 claims description 28
- 108010063045 Lactoferrin Proteins 0.000 claims description 24
- 102000010445 Lactoferrin Human genes 0.000 claims description 24
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 24
- 229940078795 lactoferrin Drugs 0.000 claims description 24
- 235000021242 lactoferrin Nutrition 0.000 claims description 24
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 19
- 208000024891 symptom Diseases 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 17
- 230000001965 increasing effect Effects 0.000 claims description 15
- 102000004338 Transferrin Human genes 0.000 claims description 13
- 108090000901 Transferrin Proteins 0.000 claims description 13
- 244000144725 Amygdalus communis Species 0.000 claims description 12
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 12
- 235000020224 almond Nutrition 0.000 claims description 12
- 239000012581 transferrin Substances 0.000 claims description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- 235000014571 nuts Nutrition 0.000 claims description 9
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 9
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 claims description 7
- 235000019486 Sunflower oil Nutrition 0.000 claims description 7
- 229940072440 bovine lactoferrin Drugs 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 7
- 239000002600 sunflower oil Substances 0.000 claims description 7
- 230000002209 hydrophobic effect Effects 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 208000025966 Neurological disease Diseases 0.000 claims description 4
- 239000005642 Oleic acid Substances 0.000 claims description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000009499 Vanilla fragrans Nutrition 0.000 claims description 4
- 235000012036 Vanilla tahitensis Nutrition 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 4
- 239000004006 olive oil Substances 0.000 claims description 4
- 235000008390 olive oil Nutrition 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 235000019502 Orange oil Nutrition 0.000 claims description 3
- 229940069765 bean extract Drugs 0.000 claims description 3
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 239000010630 cinnamon oil Substances 0.000 claims description 3
- 239000010634 clove oil Substances 0.000 claims description 3
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 3
- 239000010502 orange oil Substances 0.000 claims description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 3
- 244000290333 Vanilla fragrans Species 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 description 27
- 239000003642 reactive oxygen metabolite Substances 0.000 description 27
- -1 Fe3+ ions Chemical class 0.000 description 24
- 239000000499 gel Substances 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 150000002632 lipids Chemical class 0.000 description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 230000002354 daily effect Effects 0.000 description 15
- 239000003755 preservative agent Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 210000004556 brain Anatomy 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 12
- 230000000670 limiting effect Effects 0.000 description 12
- 230000003078 antioxidant effect Effects 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 239000000232 Lipid Bilayer Substances 0.000 description 10
- 229920002472 Starch Chemical class 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 9
- 210000003470 mitochondria Anatomy 0.000 description 9
- 230000036542 oxidative stress Effects 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 150000003904 phospholipids Chemical class 0.000 description 9
- 229940032147 starch Drugs 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 230000013632 homeostatic process Effects 0.000 description 8
- 230000036571 hydration Effects 0.000 description 8
- 238000006703 hydration reaction Methods 0.000 description 8
- 208000024714 major depressive disease Diseases 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 108010010803 Gelatin Proteins 0.000 description 7
- 230000032683 aging Effects 0.000 description 7
- 229960004756 ethanol Drugs 0.000 description 7
- 206010016256 fatigue Diseases 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 229940014259 gelatin Drugs 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 125000002252 acyl group Chemical group 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 101000807236 Human cytomegalovirus (strain AD169) Membrane glycoprotein US3 Proteins 0.000 description 5
- 208000000112 Myalgia Diseases 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 229920000615 alginic acid Polymers 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 229910001447 ferric ion Inorganic materials 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 229960003284 iron Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000000527 sonication Methods 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 239000010409 thin film Substances 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 239000002691 unilamellar liposome Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 4
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 102000007238 Transferrin Receptors Human genes 0.000 description 4
- 108010033576 Transferrin Receptors Proteins 0.000 description 4
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 4
- 230000003044 adaptive effect Effects 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 229940023476 agar Drugs 0.000 description 4
- 235000010419 agar Nutrition 0.000 description 4
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229960005069 calcium Drugs 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 229960003563 calcium carbonate Drugs 0.000 description 4
- 235000010216 calcium carbonate Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
- 230000006866 deterioration Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 230000002438 mitochondrial effect Effects 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 229920001277 pectin Polymers 0.000 description 4
- 235000010987 pectin Nutrition 0.000 description 4
- 239000001814 pectin Substances 0.000 description 4
- 150000008105 phosphatidylcholines Chemical class 0.000 description 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000010257 thawing Methods 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 230000003867 tiredness Effects 0.000 description 4
- 208000016255 tiredness Diseases 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010074051 C-Reactive Protein Proteins 0.000 description 3
- 102100032752 C-reactive protein Human genes 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 3
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 3
- 235000013162 Cocos nucifera Nutrition 0.000 description 3
- 244000060011 Cocos nucifera Species 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 240000009226 Corylus americana Species 0.000 description 3
- 235000001543 Corylus americana Nutrition 0.000 description 3
- 235000007466 Corylus avellana Nutrition 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 229930186217 Glycolipid Natural products 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 240000007049 Juglans regia Species 0.000 description 3
- 235000009496 Juglans regia Nutrition 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 244000263375 Vanilla tahitensis Species 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 3
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000004900 autophagic degradation Effects 0.000 description 3
- 235000013734 beta-carotene Nutrition 0.000 description 3
- 239000011648 beta-carotene Substances 0.000 description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 3
- 229960002747 betacarotene Drugs 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 239000001913 cellulose Chemical class 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 235000017803 cinnamon Nutrition 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000002327 glycerophospholipids Chemical class 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 230000008437 mitochondrial biogenesis Effects 0.000 description 3
- 230000004065 mitochondrial dysfunction Effects 0.000 description 3
- 230000004898 mitochondrial function Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000003463 organelle Anatomy 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 3
- 235000020234 walnut Nutrition 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 244000226021 Anacardium occidentale Species 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- 240000002791 Brassica napus Species 0.000 description 2
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 2
- 235000004936 Bromus mango Nutrition 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
- 235000009025 Carya illinoensis Nutrition 0.000 description 2
- 244000068645 Carya illinoensis Species 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010011971 Decreased interest Diseases 0.000 description 2
- 108020005199 Dehydrogenases Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000004097 EU approved flavor enhancer Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000408747 Lepomis gibbosus Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 2
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 2
- 240000000912 Macadamia tetraphylla Species 0.000 description 2
- 235000014826 Mangifera indica Nutrition 0.000 description 2
- 240000007228 Mangifera indica Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 235000003447 Pistacia vera Nutrition 0.000 description 2
- 240000006711 Pistacia vera Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 235000003434 Sesamum indicum Nutrition 0.000 description 2
- 244000040738 Sesamum orientale Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 235000009184 Spondias indica Nutrition 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 235000010358 acesulfame potassium Nutrition 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 235000012730 carminic acid Nutrition 0.000 description 2
- DGQLVPJVXFOQEV-JNVSTXMASA-N carminic acid Chemical compound OC1=C2C(=O)C=3C(C)=C(C(O)=O)C(O)=CC=3C(=O)C2=C(O)C(O)=C1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DGQLVPJVXFOQEV-JNVSTXMASA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000020226 cashew nut Nutrition 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 229920002678 cellulose Chemical class 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229930183167 cerebroside Natural products 0.000 description 2
- 150000001784 cerebrosides Chemical class 0.000 description 2
- 229960002798 cetrimide Drugs 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229940108924 conjugated linoleic acid Drugs 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 2
- SMVRDGHCVNAOIN-UHFFFAOYSA-L disodium;1-dodecoxydodecane;sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC SMVRDGHCVNAOIN-UHFFFAOYSA-L 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229960000961 floxuridine Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000019264 food flavour enhancer Nutrition 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 150000002270 gangliosides Chemical class 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000003979 granulating agent Substances 0.000 description 2
- 235000013761 grape skin extract Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229920000591 gum Polymers 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000021125 mitochondrion degradation Effects 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 2
- 235000021400 peanut butter Nutrition 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- 229940067107 phenylethyl alcohol Drugs 0.000 description 2
- 150000008103 phosphatidic acids Chemical class 0.000 description 2
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 150000008106 phosphatidylserines Chemical class 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 235000020233 pistachio Nutrition 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 235000020236 pumpkin seed Nutrition 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000022925 sleep disturbance Diseases 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 1
- WKJDWDLHIOUPPL-JSOSNVBQSA-N (2s)-2-amino-3-({[(2r)-2,3-bis(tetradecanoyloxy)propoxy](hydroxy)phosphoryl}oxy)propanoic acid Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCC WKJDWDLHIOUPPL-JSOSNVBQSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- WOAHJDHKFWSLKE-UHFFFAOYSA-N 1,2-benzoquinone Chemical compound O=C1C=CC=CC1=O WOAHJDHKFWSLKE-UHFFFAOYSA-N 0.000 description 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 1
- WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 description 1
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 1
- OZSITQMWYBNPMW-GDLZYMKVSA-N 1,2-ditetradecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCC OZSITQMWYBNPMW-GDLZYMKVSA-N 0.000 description 1
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 1
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
- PAZGBAOHGQRCBP-ZCXUNETKSA-N 1-Palmitoyl-2-oleoylglycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC PAZGBAOHGQRCBP-ZCXUNETKSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- WGIMXKDCVCTHGW-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCCO WGIMXKDCVCTHGW-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- NEZDNQCXEZDCBI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(tetradecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 240000006054 Agastache cana Species 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 235000006667 Aleurites moluccana Nutrition 0.000 description 1
- 244000136475 Aleurites moluccana Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- 101100072002 Arabidopsis thaliana ICME gene Proteins 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 235000012284 Bertholletia excelsa Nutrition 0.000 description 1
- 244000205479 Bertholletia excelsa Species 0.000 description 1
- 229930185605 Bisphenol Natural products 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- 240000004355 Borago officinalis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101000766308 Bos taurus Serotransferrin Proteins 0.000 description 1
- 206010050012 Bradyphrenia Diseases 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 244000188595 Brassica sinapistrum Species 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000005747 Carum carvi Nutrition 0.000 description 1
- 240000000467 Carum carvi Species 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 241000132536 Cirsium Species 0.000 description 1
- GJUABKCEXOMRPQ-FMQUCBEESA-N Citrus Red No.2 Chemical compound COC1=CC=C(OC)C(\N=N\C=2C3=CC=CC=C3C=CC=2O)=C1 GJUABKCEXOMRPQ-FMQUCBEESA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 235000010919 Copernicia prunifera Nutrition 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 1
- KLFKZIQAIPDJCW-HTIIIDOHSA-N Dipalmitoylphosphatidylserine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-HTIIIDOHSA-N 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 241000271571 Dromaius novaehollandiae Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 239000000940 FEMA 2235 Substances 0.000 description 1
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
- 206010016374 Feelings of worthlessness Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 102000004263 Glutamate-Cysteine Ligase Human genes 0.000 description 1
- 108010081687 Glutamate-cysteine ligase Proteins 0.000 description 1
- 108010036164 Glutathione synthase Proteins 0.000 description 1
- 102100034294 Glutathione synthetase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 241000384508 Hoplostethus atlanticus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-L IMP(2-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-L 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 235000005590 Larix decidua Nutrition 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- CKZXONNJVHXSQM-UHFFFAOYSA-N Ledol Natural products CC(C)C1CCC(C)(O)C2C3CC(C)CC123 CKZXONNJVHXSQM-UHFFFAOYSA-N 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 241001072282 Limnanthes Species 0.000 description 1
- 235000012854 Litsea cubeba Nutrition 0.000 description 1
- 240000002262 Litsea cubeba Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 102100027329 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Human genes 0.000 description 1
- 101710137760 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- RWKUXQNLWDTSLO-GWQJGLRPSA-N N-hexadecanoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC RWKUXQNLWDTSLO-GWQJGLRPSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- CWEKGCILYDRKNV-KPOOZVEVSA-L Orange B Chemical compound [Na+].[Na+].CCOC(=O)c1[nH]n(-c2ccc(cc2)S([O-])(=O)=O)c(=O)c1\N=N\c1ccc(c2ccccc12)S([O-])(=O)=O CWEKGCILYDRKNV-KPOOZVEVSA-L 0.000 description 1
- 235000014643 Orbignya martiana Nutrition 0.000 description 1
- 244000021150 Orbignya martiana Species 0.000 description 1
- 208000004056 Orthostatic intolerance Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010057244 Post viral fatigue syndrome Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 231100000991 Reactive Oxygen Species (ROS) Photosafety Assay Toxicity 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 240000000513 Santalum album Species 0.000 description 1
- 235000008632 Santalum album Nutrition 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 206010043169 Tearfulness Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 235000007769 Vetiveria zizanioides Nutrition 0.000 description 1
- 244000284012 Vetiveria zizanioides Species 0.000 description 1
- TUWWTQRJWLLWJE-UHFFFAOYSA-N Viridiflorol Natural products CC1CCC2C1C3C(CCC2(O)O)C3(C)C TUWWTQRJWLLWJE-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 1
- BPHQZTVXXXJVHI-IADGFXSZSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-tetradecanoyloxypropyl] tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-IADGFXSZSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229960001040 ammonium chloride Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940105969 annatto extract Drugs 0.000 description 1
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 230000037358 bacterial metabolism Effects 0.000 description 1
- 235000001053 badasse Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 235000019481 bixa orellana extract Nutrition 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 229960003168 bronopol Drugs 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- YPCRNBPOUVJVMU-LCGAVOCYSA-L calcium glubionate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YPCRNBPOUVJVMU-LCGAVOCYSA-L 0.000 description 1
- 229960002283 calcium glubionate Drugs 0.000 description 1
- 229940078512 calcium gluceptate Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 229940078480 calcium levulinate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- FATUQANACHZLRT-XBQZYUPDSA-L calcium;(2r,3r,4s,5r,6r)-2,3,4,5,6,7-hexahydroxyheptanoate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C([O-])=O FATUQANACHZLRT-XBQZYUPDSA-L 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000001325 capsicum annuum l. var. longum oleoresin Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 230000006721 cell death pathway Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000800 cetrimonium bromide Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 229960005443 chloroxylenol Drugs 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000013986 citrus red 2 Nutrition 0.000 description 1
- 239000001679 citrus red 2 Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000009668 clonal growth Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019516 cod Nutrition 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- CGMRCMMOCQYHAD-UHFFFAOYSA-J dicalcium hydroxide phosphate Chemical compound [OH-].[Ca++].[Ca++].[O-]P([O-])([O-])=O CGMRCMMOCQYHAD-UHFFFAOYSA-J 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- BPHQZTVXXXJVHI-UHFFFAOYSA-N dimyristoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-UHFFFAOYSA-N 0.000 description 1
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 1
- FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PVBRXXAAPNGWGE-LGVAUZIVSA-L disodium 5'-guanylate Chemical compound [Na+].[Na+].C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP([O-])([O-])=O)[C@@H](O)[C@H]1O PVBRXXAAPNGWGE-LGVAUZIVSA-L 0.000 description 1
- 239000004198 disodium guanylate Substances 0.000 description 1
- 235000013896 disodium guanylate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000004194 disodium inosinate Substances 0.000 description 1
- 235000013890 disodium inosinate Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 1
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000007911 effervescent powder Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- WGTRJVCFDUCKCM-UHFFFAOYSA-N ent-ledene Natural products C1CC2C(C)(C)C2C2C(C)CCC2=C1C WGTRJVCFDUCKCM-UHFFFAOYSA-N 0.000 description 1
- 231100000317 environmental toxin Toxicity 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000019240 fast green FCF Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000007983 food acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 239000010460 hemp oil Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid group Chemical group C(CCCCCC)(=O)O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid group Chemical group C(CCCCC)(=O)O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229960004867 hexetidine Drugs 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 229940113174 imidurea Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 244000056931 lavandin Species 0.000 description 1
- 235000009606 lavandin Nutrition 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229960000816 magnesium hydroxide Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000013987 orange B Nutrition 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 235000012658 paprika extract Nutrition 0.000 description 1
- DYUUPIKEWLHQGQ-SDXBLLFJSA-N paprika oleoresin Chemical compound C(\[C@]12[C@@](O1)(C)C[C@@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=C[C@H]1C(C)=C[C@H](O)CC1(C)C DYUUPIKEWLHQGQ-SDXBLLFJSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000003784 poor nutrition Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229960004109 potassium acetate Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 229940103091 potassium benzoate Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- 229960004839 potassium iodide Drugs 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 229940043349 potassium metabisulfite Drugs 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- 229940096992 potassium oleate Drugs 0.000 description 1
- 229940093916 potassium phosphate Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- MLICVSDCCDDWMD-KVVVOXFISA-M potassium;(z)-octadec-9-enoate Chemical compound [K+].CCCCCCCC\C=C/CCCCCCCC([O-])=O MLICVSDCCDDWMD-KVVVOXFISA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 230000008433 psychological processes and functions Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000006950 reactive oxygen species formation Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000010282 redox signaling Effects 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940108461 rennet Drugs 0.000 description 1
- 108010058314 rennet Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008866 synergistic binding Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000010679 vetiver oil Substances 0.000 description 1
- AYXPYQRXGNDJFU-IMNVLQEYSA-N viridiflorol Chemical compound [C@@H]1([C@@](CC[C@@H]2[C@H]3C2(C)C)(C)O)[C@H]3[C@H](C)CC1 AYXPYQRXGNDJFU-IMNVLQEYSA-N 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 150000003772 α-tocopherols Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
Definitions
- Adaptive homeostasis is a phenomenon, shared across cells and tissues of both simple and complex organisms, that enables the expansion or contraction of the homeostatic range to modulate stress-protective systems in response to varying internal and external environments.
- the homeostasis can be disrupted due to an imbalance in the stress and stress protective mechanisms.
- This dysregulation of adaptive homeostasis in the final third of lifespan is a factor in the ageing process and stress associated disease, while successful maintenance or restoration of adaptive homeostasis can result in extended, healthy longevity.
- compositions and methods for use in treating a subject can include glutathione, coenzyme Q10 (CoQ10), pyrroloquinoline quinone, iron binding glycoprotein or any combination thereof.
- concentration of glutathione can be about 10 mg/ml to 100 mg/ml. In some embodiments, the concentration of glutathione can be about 22 mg/ml. In some embodiments, the concentration of CoQ10 can be about 10 mg/ml to 100 mg/ml. In some embodiments, the concentration of CoQ10 can be about 22 mg/ml. In some embodiments, the concentration of pyrroloquinoline quinone can be about 1 mg to 10 mg.
- the concentration of pyrroloquinoline quinone can be about 2 mg/ml.
- the iron binding glycoprotein can be lactoferrin or transferrin.
- the iron binding glycoprotein can be lactoferrin.
- lactoferrin is a bovine lactoferrin.
- the concentration of bovine lactoferrin can be about 5 mg/ml to 50 mg/ml. In some embodiments, the concentration of bovine lactoferrin can be about 7 mg/ml.
- formulations comprising the compositions and at least one excipient.
- the excipient can be glycerin, oleic acid (from olive oil), natural clove oil, orange oil, cinnamon oil, vitamin E, milk and/or vanilla bean extract.
- the formulation can be prepared as a liposome.
- the liposomes can include phosphatidylcholine.
- the formulations can be present within a gel.
- the gel can include nut butter and/or an oil.
- the nut butter can be almond butter.
- the oil can be medium chain triglyceride (MCT) oil and/or sunflower oil.
- MCT medium chain triglyceride
- a gel can include almond butter, MCT oil and/or sunflower oil.
- the compositions can be used to treat Chronic Fatigue Syndrome (CFS).
- CFS Chronic Fatigue Syndrome
- the compositions can improve one or more symptoms associated with CFS.
- the composition can be administered for about 50-150 days, for example, for about 30 days, 60 days, 90 days or more.
- Methods of treatment of diseases such as, but not limited to, cardiovascular diseases, diabetes, cancer, chronic kidney disease, chronic obstructive pulmonary disease (COPD), and/or neurological diseases are also provided herein.
- the present disclosure also provides a method of increasing healthspan or lifespan in a subject by administering the compositions of the disclosure.
- Figure 1 shows adaptive responses in various age groups.
- Figure 2 is an example of the formulation of the disclosure prepared as a liposome.
- ROS Reactive oxygen species
- ROS reactive oxygen species
- ROS reactive oxygen species
- cells can produce numerous ROS, and the living organisms eventually evolve a series of response mechanisms to adapt to the ROS exposure as well as utilize it as the signaling molecules.
- ROS molecules can also trigger oxidative stress in a feedback mechanism involving many biological processes, such as apoptosis, necrosis and autophagy.
- ROS can play a role as the signaling molecules in the cell death pathway. Overwhelming production of ROS can destroy organelle’s structure and biomolecules, which also leads to inflammatory responses. Oxidative damage ensues when the generation of free radicals and reactive oxygen and nitrogen species exceeds the capacity of cellular defense mechanisms.
- Organisms are equipped with mechanisms to combat ROS. As organisms age, there an imbalance between the systemic manifestation of ROS and the organism’s ability to readily detoxify ROS or to repair the resulting damage. This imbalance is referred to as oxidative stress. Mitochondria play a critical role in combatting ROS. However, mitochondrial biogenesis declines with age due to alterations in mitochondrial dynamics and inhibition of mitophagy, an autophagy process that removes dysfunctional mitochondria. Age-dependent abnormalities in mitochondrial quality control further weaken and impair mitochondrial function. In addition, with advanced chronological age, antioxidant concentrations in blood can decline leading to an increase in reactive oxygen species (ROS).
- ROS reactive oxygen species
- ROS reactive oxygen species
- biomolecules and cellular organelles which lead to chronic age-related conditions such as neurodegenerative diseases, cancer, diabetes, and kidney disease.
- ROS reactive oxygen species
- the nerve cells from brain and spinal cord can suffer from mitochondrial dysfunctions as well as exci to toxicity and finally apoptosis, which lead to either functional loss or sensory dysfunctions.
- the brain has a high metabolic rate and relatively reduced capacity for cellular regeneration, nerve cells in the brain area are particularly susceptible to damage by ROS.
- free radicals and oxidative stress can work together to accelerate aging and increase the risk of diseases e.g., fatigue, cancer, inflammatory joint disease, dementia, asthma and diabetes among others.
- compositions that can combat oxidative stress and prevent or reduce the incidence of diseases and conditions associated with increased oxidative stress.
- compositions of glutathione (GSH), CoQ10, pyrroloquinoline quinone, and/or iron binding glycoproteins for restoring adaptive homeostasis by up-regulating aging related pathways and related gene expressions.
- the compositions of the disclosure can reduce or prevent the decline of biological homeostasis and adaptability by upregulating detoxification pathways such as mitophagy, autophagy and ROS and down regulating mTOR, insulin and AMPK, while increasing the density and number of mitochondria and increasing the efficiency of their electron transport.
- the compositions of the disclosure can include glutathione
- glutathione is reduced glutathione (GSH).
- GSH glutathione
- glutathione and reduced glutathione can be used interchangeably and are used to indicate the reduced form, GSH.
- Glutathione is a fundamental antioxidant that reduces ROS within the body, protecting cells and preventing tissue damage.
- Glutathione is an abundant antioxidant and a major detoxification agent in cells.
- GSH can be synthesized by the sequential addition of the precursor amino acids, cysteine (Cys), glutamic acid (Glu) and glycine (Gly) through two- enzyme reactions catalyzed by glutamate cysteine ligase and glutathione synthetase.
- GSH levels are regulated in response to redox change. It plays a role in cell growth, proliferation, apoptosis and signaling, particularly redox signaling.
- GSH acts as an antioxidant in two ways, it directly reacts non-enzymatically with free radicals such as superoxide radical (O2"), NO, or hydroxyl ion (OH”) and it indirectly functions as a reducing agent by donating an electron to H2O2 for its reduction to water and O2 in the presence of glutathione peroxidase (GPx) enzyme. Due to its potential cytoprotective functions there has been great interest in increasing GSH via analogs and precursors. Accordingly, GSH can play a role in protecting neuronal tissue, pulmonary cells and cardiovascular structures by enhancing GSH-related detoxification capacity.
- free radicals such as superoxide radical (O2"), NO, or hydroxyl ion (OH)
- GPx glutathione peroxidase
- GSH low GSH levels can impair immune function. GSH is also involved in the maintenance of optimal cytokine levels. GSH depletion can lead to an increase in pro- inflammatory cytokines i.e., tumor necrosis factor-a (TNF-a), lnterleukin-1 p (IL-1 p) and IL-6 gene expression but may not affect levels of anti-inflammatory cytokines such as IL-10.
- TNF-a tumor necrosis factor-a
- IL-1 p lnterleukin-1 p
- IL-6 anti-inflammatory cytokines
- Low levels of GSH can be associated with exposure to oxidants/drugs/toxins, poor nutrition and other factors. GSH levels are also dependent on the availability of its precursor amino acids, Cys, Glu and Gly, with Cys most often considered as rate limiting.
- GSH intracellular GSH levels can be depleted in certain tissues, including the liver, by short periods of fasting such as that which occurs overnight. Additionally, GSH is the most abundant brain antioxidant and altered GSH can be a key aspect of the pathogenesis of mild cognitive impairment, many neurological disorders and Alzheimer’s disease. Furthermore, higher GSH levels have been identified in the brains of older adults compared to their younger counterparts, suggesting that the higher GSH levels are present to help offset the age-related increases in oxidative stress and therefore maintain redox homeostasis.
- compositions of the disclosure can include CoQ10.
- CoQ10 can improve the speed and efficiency of mitochondria facilitating more energy transfer and energy availability at a cellular level.
- Coenzyme Q10 also known as ubiquinone
- CoQ10 is a lipid-soluble vitamin-like compound. CoQ10 is present in the inner membrane of the mitochondria of the cell. High levels of CoQ10 is found in high energy cells such as heart, brain, liver, and kidney cells. In the aging process, cellular production of CoQ10 decreases.
- CoQ10 acts as a regenerating antioxidant, helping to quench free radicals and prevent lipid peroxidation.
- CoQ10 is a mitochondrial energy coupler, which is part of the cellular process for synthesizing adenosine triphosphate (ATP), the body’s main source of energy.
- ATP adenosine triphosphate
- CoQ10 can also support cognitive function.
- CoQIO s antioxidant activity also has neuroprotective effects by protecting against oxidative stress in the mitochondria of brain cells.
- CoQ10 can also attenuate oxidative damage in the mitochondria to reduce cognitive effects associated with normal brain aging, and to supplement spatial learning.
- CoQ10 can decrease hepatic mRNA expression of IL-6 and TNF-a, to attenuate the level of C-reactive protein (CRP) in rodent models.
- CoQ10 supplementation with doses ranging from about 100-500 mg/day can increase the serum level of CoQ10, and decrease TNF-a, but no substantial difference is observed in CRP.
- CoQ10 oral administration can provide beneficial effects on a range of different disorders that have been associated with low CoQ10 levels and high oxidative stress, such as, but not limited to, mitochondrial, cardiovascular, and neurodegenerative diseases.
- compositions of the disclosure can include pyrroloquinoline quinone (PQQ), an aromatic tricyclic o-quinone that serves as a redox cofactor of a number of prokaryotic dehydrogenases, such as alcohol and sugar dehydrogenases.
- PQQ can exert pro-oxidant actions by the formation of reactive oxygen species (ROS), such as O2- and H2O2, via its redox cycling under certain conditions.
- ROS reactive oxygen species
- PQQ can influence energy-related metabolism and neurologic functions in animals. The mechanism of action involves interactions with cell signaling pathways and mitochondrial function.
- PQQ has anti-oxidative and mitochondrial biogenesis capacities. Reduced PQQ can provide strong antioxidant capacity.
- the antioxidant capacity can be greater than ascorbic acid, by about 2 times, 3 times, 4 times, 5 times, 6 times, 7, times, 8 times, 9 times or 10 times.
- the antioxidant capacity of the compositions of the disclosure can be about 7.4 times greater than ascorbic acid. Increasing PQQ levels can trigger the growth of new mitochondria and nerve cells with strong neuroprotective signals.
- compositions of the disclosure can include iron binding glycoproteins.
- the iron binding glycoprotein is used for absorption via the jejunum (the second part of the small intestine).
- the iron binding glycoprotein can be a synthetic iron binding glycoprotein, a recombinant iron binding glycoprotein or a natural iron binding glycoprotein.
- the iron binding glycoprotein can be derived from any mammal. In some embodiments, the iron binding glycoprotein can be derived from a cow, human, monkey, dog, cat, mouse, rat, guinea pig, and/or hamster.
- the iron binding glycoprotein can be lactoferrin or transferrin.
- the iron binding glycoprotein can be lactoferrin.
- Lactoferrin is a cationic iron-binding glycoprotein with molecular weight of about 77-80 kDa. Lactoferrin is folded into two globular lobes connected by an a-helical bridge and stabilized by a number of disulfide bonds. The main function of this protein is to control and regulate the concentration of free iron in biological fluids via its ability to either solubilize or sequester ferric ions (Fe 3+ ). LF can be either extracted from milk or produced by recombinant techniques in microorganisms for use in the compositions of the disclosure.
- one LF molecule can typically binds two Fe 3+ ions, which greatly depends on the synergistic binding of two HCOs " or CO3 2 ".
- In vitro iron release can be enhanced from LF molecule by lowering the pH or using chelating agents.
- structure analysis of LF revealed that it is composed of 2 lobes. Each lobe includes 2 domains separated by a cleft that can cobind Fe 3+ and CO3 2 ".
- the binding and the release of substrates is usually associated with conformational changes including opening and closing of the interdomain cleft.
- Two carbohydrate attachment sites are present on the LF molecule, one in each lobe.
- the first [3- a-p unit (residues 1 to 40) includes about nine basic sidechains protruding from the surface (most near the C terminus of helix A) which seems to be a receptor binding moiety, responsible for receptor recognition of LF.
- lactoferrin can be bovine lactoferrin (UniProt ID: Q6LBN7).
- the lactoferrin can be ENSEMBL translation ID ENSP00000231751.4, ENSP00000395234.1 , ENSP00000397427.1 , ENSP00000405546.1 , ENSP00000405719.2, ENSP00000508000.1 , a portion, or a variant thereof.
- the iron binding glycoprotein can be transferrin. Presence of transferrin in the compositions can allow the safe transfer of the compositions through the gastric environment. Human transferrin is a single-chain glycoprotein.
- Transferrin binds two Fe 3+ ions, with high affinity (Kd ⁇ 10-20 M), together with two synergistically bound COs 2- ions.
- the protein is mainly synthesized in the liver and secreted into the plasma. Lower amounts are also produced in other organs, such as the testis and brain.
- Transferrin can also act as a cytokine.
- transferrin has been identified as one of the factors that promote the clonal growth of the precursors of murine granulocytes and macrophages cultured in vitro under serum-free conditions.
- the compositions of the disclosure can include the entire transferrin protein or a fragment thereof.
- the transferrin can be ENSEMBL Translation ID ENSP00000385834.3, ENSP00000419338.1 , ENSP00000417468.1 , a portion thereof or a variant thereof.
- transferrin is responsible for the transport of iron and controls the level of iron in biological fluids.
- Transferrin-receptors (TfR) on cell surfaces can bind Tf with high affinity and internalize into the cell.
- Transferrin receptor (TfR) can also transport transferrin across the blood-brain barrier (BBB), which can be exploited to deliver the compositions of the disclosure from the bloodstream into the brain.
- BBB blood-brain barrier
- transferrin can be bovine transferrin or human transferrin.
- an iron binding protein can be covalently or non-covalently linked to glutathione, coenzyme Q10 (CoQ10), pyrroloquinoline quinone, or combinations thereof.
- compositions of the disclosure can include a combination comprising one or more of glutathione, CoQ10, pyrroloquinoline quinone and/or iron binding glycoprotein.
- Compositions can be prepared in an oxygen deprived environment to prevent oxidation of the composition.
- the compositions can include glutathione in the amount of from about 0.1 mg to 1 mg, about 0.5 mg to 5 mg, 1 mg to 10 mg, 5 mg to 50 mg, 10 mg to 100 mg, 50 mg to 150 mg, 100 mg to 200 mg, 150 mg to 250 mg, 200 mg to 300 mg, 250 mg to 350 mg, 300 mg to 400 mg, 350 mg to 450 mg, 400 mg to 500 mg, 450 mg to 550 mg, 500 mg to 600 mg, 550 mg to 650 mg, 600 mg to 700 mg, 650 mg to 750 mg, 700 mg to 800 mg, 850 mg to 950 mg, 900 mg to 1000 mg or more.
- the compositions can include glutathione in the amount of 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, or more. In some embodiments, the compositions can include glutathione in the amount of 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg, or 300 mg.
- the compositions can include glutathione in the amount of from about 0.1 mg/ml to 1 mg/ml, about 0.5 mg/ml to 5 mg/ml, 1 mg/ml to 10 mg/ml, 5 mg/ml to 50 mg/ml, 10 mg/ml to 100 mg/ml, 50 mg/ml to 150 mg/ml, 100 mg/ml to 200 mg/ml, 150 mg/ml to 250 mg/ml, 200 mg/ml to 300 mg/ml, 250 mg/ml to 350 mg/ml, 300 mg/ml to 400 mg/ml, 350 mg/ml to 450 mg/ml, 400 mg/ml to 500 mg/ml, 450 mg/ml to 550 mg/ml, 500 mg/ml to 600 mg/ml, 550 mg/ml to 650 mg/ml, 600 mg/ml to 700 mg/ml, 650 mg/ml to 750 mg/ml, 700 mg/ml
- the compositions can include glutathione in the amount of 10 mg/ml, 20 mg/ml, 30 mg/ml, 40 mg/ml, 50 mg/ml, 60 mg/ml, 70 mg/ml, 80 mg/ml, 90 mg/ml, 100 mg/ml, 200 mg/ml, 300 mg/ml, 400 mg/ml, 500 mg/ml, 600 mg/ml, 700 mg/ml, 800 mg/ml, or more.
- the compositions can include glutathione in the amount of 15 mg/ml, 16 mg/ml, 17 mg/ml, 18 mg/ml, 19 mg/ml, 20 mg/ml, 21 mg/ml, 22 mg/ml, 23 mg/ml, 24 mg/ml, 25 mg/ml, 26 mg/ml, 27 mg/ml, 28 mg/ml, 29 mg/ml, 30 mg/ml, 31 mg/ml, 32 mg/ml, 33 mg/ml, 34 mg/ml, 35 mg/ml, 36 mg/ml, 37 mg/ml, 38 mg/ml, 39 mg/ml, or 40 mg/ml.
- the compositions can include CoQ10 in the amount of from about 0.1 mg to 1 mg, about 0.5 mg to 5 mg, 1 mg to 10 mg, 5 mg to 50 mg, 10 mg to 100 mg, 50 mg to 150 mg, 100 mg to 200 mg, 150 mg to 250 mg, 200 mg to 300 mg, 250 mg to 350 mg, 300 mg to 400 mg, 350 mg to 450 mg, 400 mg to 500 mg, 450 mg to 550 mg, 500 mg to 600 mg, 550 mg to 650 mg, 600 mg to 700 mg, 650 mg to 750 mg, 700 mg to 800 mg, 850 mg to 950 mg, 900 mg to 1000 mg or more.
- the compositions can include CoQ10 in the amount of 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, or more. In some embodiments, the compositions can include CoQ10 in the amount of 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg, or 300 mg.
- the compositions can include CoQ10 in the amount of from about 0.1 mg/ml to 1 mg/ml, about 0.5 mg/ml to 5 mg/ml, 1 mg/ml to 10 mg/ml, 5 mg/ml to 50 mg/ml, 10 mg/ml to 100 mg/ml, 50 mg/ml to 150 mg/ml, 100 mg/ml to 200 mg/ml, 150 mg/ml to 250 mg/ml, 200 mg/ml to 300 mg/ml, 250 mg/ml to 350 mg/ml, 300 mg/ml to 400 mg/ml, 350 mg/ml to 450 mg/ml, 400 mg/ml to 500 mg/ml, 450 mg/ml to 550 mg/ml, 500 mg/ml to 600 mg/ml, 550 mg/ml to 650 mg/ml, 600 mg/ml to 700 mg/ml, 650 mg/ml to 750 mg/ml, 700 mg/ml to
- the compositions can include CoQ10 in the amount of 10 mg/ml, 20 mg/ml, 30 mg/ml, 40 mg/ml, 50 mg/ml, 60 mg/ml, 70 mg/ml, 80 mg/ml, 90 mg/ml, 100 mg/ml, 200 mg/ml, 300 mg/ml, 400 mg/ml, 500 mg/ml, 600 mg/ml, 700 mg/ml, 800 mg/ml, or more.
- the compositions can include CoQ10 in the amount of 15 mg/ml, 16 mg/ml, 17 mg/ml, 18 mg/ml, 19 mg/ml, 20 mg/ml, 21 mg/ml, 22 mg/ml, 23 mg/ml, 24 mg/ml, 25 mg/ml, 26 mg/ml, 27 mg/ml, 28 mg/ml, 29 mg/ml, 30 mg/ml, 31 mg/ml, 32 mg/ml, 33 mg/ml, 34 mg/ml, 35 mg/ml, 36 mg/ml, 37 mg/ml, 38 mg/ml, 39 mg/ml, or 40 mg/ml.
- the compositions can include pyrroloquinoline quinone in the amount of from about 0.1 mg to 1 mg, about 0.5 mg to 5 mg, 1 mg to 10 mg, 5 mg to 50 mg, 10 mg to 100 mg, 50 mg to 150 mg, 100 mg to 200 mg, 150 mg to 250 mg, 200 mg to 300 mg, 250 mg to 350 mg, 300 mg to 400 mg, 350 mg to 450 mg, 400 mg to 500 mg, 450 mg to 550 mg, 500 mg to 600 mg, 550 mg to 650 mg, 600 mg to 700 mg, 650 mg to 750 mg, 700 mg to 800 mg, 850 mg to 950 mg, 900 mg to 1000 mg or more.
- the compositions can include pyrroloquinoline quinone in the amount of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, or more.
- the compositions can include CoQ10 in the amount of 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, or 30 mg.
- the compositions can include pyrroloquinoline quinone in the amount of from about 0.1 mg/ml to 1 mg/ml, about 0.5 mg/ml to 5 mg/ml, 1 mg/ml to 10 mg/ml, 5 mg/ml to 50 mg/ml, 10 mg/ml to 100 mg/ml, 50 mg/ml to 150 mg/ml, 100 mg/ml to 200 mg/ml, 150 mg/ml to 250 mg/ml, 200 mg/ml to 300 mg/ml, 250 mg/ml to 350 mg/ml, 300 mg/ml to 400 mg/ml, 350 mg/ml to 450 mg/ml, 400 mg/ml to 500 mg/ml, 450 mg/ml to 550 mg/ml, 500 mg/ml to 600 mg/ml, 550 mg/ml to 650 mg/ml, 600 mg/ml to 700 mg/ml, 650 mg/ml to 750 mg/ml,
- the compositions can include pyrroloquinoline quinone in the amount of 1 mg/ml, 2 mg/ml, 3 mg/ml, 4 mg/ml, 5 mg/ml, 6 mg/ml, 7 mg/ml, 8 mg/ml, 9 mg/ml, 10 mg/ml, 20 mg/ml, 30 mg/ml, 40 mg/ml, 50 mg/ml, 60 mg/ml, 70 mg/ml, 80 mg/ml, or more.
- the compositions can include pyrroloquinoline quinone in the amount of 1.5 mg/ml, 1.6 mg/ml, 1.7 mg/ml, 1.8 mg/ml, 1.9 mg/ml, 2.0 mg/ml, 2.1 mg/ml, 2.2 mg/ml, 2.3 mg/ml, 2.4 mg/ml, 2.5 mg/ml, 2.6 mg/ml, 2.7 mg/ml, 2.8 mg/ml, 2.9 mg/ml, 3.0 mg/ml, 3.1 mg/ml, 3.2 mg/ml, 3.3 mg/ml, 3.4 mg/ml, 3.5 mg/ml, 3.6 mg/ml, 3.7 mg/ml, 3.8 mg/ml, 3.9 mg/ml, or 4.0 mg/ml.
- the compositions can include iron binding glycoprotein in the amount of from about 0.1 mg to 1 mg, about 0.5 mg to 5 mg, 1 mg to 10 mg, 5 mg to 50 mg, 10 mg to 100 mg, 50 mg to 150 mg, 100 mg to 200 mg, 150 mg to 250 mg, 200 mg to 300 mg, 250 mg to 350 mg, 300 mg to 400 mg, 350 mg to 450 mg, 400 mg to 500 mg, 450 mg to 550 mg, 500 mg to 600 mg, 550 mg to 650 mg, 600 mg to 700 mg, 650 mg to 750 mg, 700 mg to 800 mg, 850 mg to 950 mg, 900 mg to 1000 mg or more.
- the compositions can include iron binding glycoprotein in the amount of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, or more. In some embodiments, the compositions can include iron binding glycoprotein in the amount of 65 mg, 66 mg, 67 mg, 68 mg, 69 mg, 70 mg, 71 mg, 72 mg, 73 mg, 74 mg, 75 mg, 76 mg, 77 mg, 78 mg, 79 mg, or 80 mg.
- the compositions can include iron binding glycoprotein in the amount of from about 0.1 mg/ml to 1 mg/ml, about 0.5 mg/ml to 5 mg/ml, 1 mg/ml to 10 mg/ml, 5 mg/ml to 50 mg/ml, 10 mg/ml to 100 mg/ml, 50 mg/ml to 150 mg/ml, 100 mg/ml to 200 mg/ml, 150 mg/ml to 250 mg/ml, 200 mg/ml to 300 mg/ml, 250 mg/ml to 350 mg/ml, 300 mg/ml to 400 mg/ml, 350 mg/ml to 450 mg/ml, 400 mg/ml to 500 mg/ml, 450 mg/ml to 550 mg/ml, 500 mg/ml to 600 mg/ml, 550 mg/ml to 650 mg/ml, 600 mg/ml to 700 mg/ml, 650 mg/ml to 750 mg/ml, 700 mg/ml
- the compositions can include iron binding glycoprotein in the amount of 1 mg/ml, 2 mg/ml, 3 mg/ml, 4 mg/ml, 5 mg/ml, 6 mg/ml, 7 mg/ml, 8 mg/ml, 9 mg/ml, 10 mg/ml, 20 mg/ml, 30 mg/ml, 40 mg/ml, 50 mg/ml, 60 mg/ml, 70 mg/ml, 80 mg/ml, or more.
- the compositions can include pyrroloquinoline quinone in the amount of 5 mg/ml, 5.5 mg/ml, 6 mg/ml, 6.5 mg/ml, 7 mg/ml, 7.5 mg/ml, 8 mg/ml, 8.5 mg/ml, 9 mg/ml, 9.5 mg/ml, 10 mg/ml, 10.5 mg/ml, 11 mg/ml, 11.5 mg/ml, 12 mg/ml, 12.5 mg/ml, 13 mg/ml, 13.5 mg/ml, 14 mg/ml, 14.5 mg/ml, 15 mg/ml, 15.5 mg/ml, 16 mg/ml, 16.5 mg/ml, 17 mg/ml, 17.5 mg/ml, 18 mg/ml, 18.5 mg/ml, 19 mg/ml, 19.5 mg/ml or more.
- compositions of the disclosure can include the following components: glutathione (about 100, 200, 220, 300, or 400 mg); CoQ10 (about 100, 200, 220, 300, or400 mg), pyrroloquinoline quinone (about 5, 10, 15, 20, 30, or40 mg) and/or iron binding glycoprotein e.g., lactoferrin (about 40, 50, 60, 70, 80, 90, or 100 mg).
- the compositions can include glutathione (about 15, 20, 22, 25, 30, or 40 mg/ml); CoQ10 (about 15, 20, 22, 25, 30 or 40 mg/ml), pyrroloquinoline quinone (about 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, or 3.5 mg/ml) and/or iron binding glycoprotein e.g., lactoferrin (about 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg/ml).
- glutathione about 15, 20, 22, 25, 30, or 40 mg/ml
- CoQ10 about 15, 20, 22, 25, 30 or 40 mg/ml
- pyrroloquinoline quinone about 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, or 3.5 mg/ml
- iron binding glycoprotein e.g., lactoferrin (about 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg/ml).
- the compositions of the disclosure can include the following components: glutathione (about 220 mg); CoQ10 (about 220 mg), pyrroloquinoline quinone (about 20 mg) and/or iron binding glycoprotein e.g., lactoferrin (about 70 mg).
- the compositions can include glutathione (about 22 mg/ml); CoQ10 (about 22 mg/ml), pyrroloquinoline quinone (about 2 mg/ml) and/or iron binding glycoprotein e.g., lactoferrin (about 7 mg/ml).
- compositions can be administered to humans, human patients or subjects.
- formulations are principally directed to formulations which are suitable for administration to humans, it will be understood by the skilled artisan that such therapeutic agents are generally suitable for administration to any other animal, e.g., to non-human animals, e.g., non-human mammals. Modifications of formulations can be used such that they are suitable for administration to humans.
- Formulations of compositions of glutathione, CoQ10, pyrroloquinoline quinone and/or iron binding glycoprotein described herein can be prepared by any method known or hereafter developed in the art of pharmacology.
- such preparatory methods include the step of bringing the glutathione, CoQ10, pyrroloquinoline quinone and/or iron binding glycoprotein into association with an excipient and/or one or more other accessory ingredients, and then, if necessary and/or desirable, dividing, shaping and/or packaging the product into a desired single- or multi-dose unit.
- the single-dose unit can be 10 ml.
- a formulation in accordance with the disclosure can be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses.
- a “unit dose” is discrete amount of the formulation comprising a predetermined amount of the compositions of glutathione, CoQ10, pyrroloquinoline quinone and/or iron binding glycoprotein.
- the amount of glutathione, CoQ10, pyrroloquinoline quinone and/or iron binding glycoprotein is generally equal to the dosage which would be administered to a subject and/or a convenient fraction of such a dosage such as, for example, one-half or one- third of such a dosage.
- Relative amounts of one or more of glutathione, CoQ10, pyrroloquinoline quinone and/or iron binding glycoprotein, the excipients, and/or any additional ingredients in a formulation in accordance with the disclosure can vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the formulation is to be administered.
- the formulation can include between 0.1 % and 100%, e.g., between .5 and 50%, between 1-30%, between 5-80%, or, in some embodiments, at least 20%, at least 40%, at least 60%, or at least 80% (w/w) of one or more of glutathione, CoQ10, pyrroloquinoline quinone and/or iron binding glycoprotein.
- compositions of glutathione, CoQ10, pyrroloquinoline quinone and/or iron binding glycoprotein of the present disclosure can be formulated using one or more excipients to: (1) increase stability; (2) permit the sustained or delayed release; (3) alter the biodistribution; (4) alter the release profile of glutathione, CoQ10, pyrroloquinoline quinone and/or iron binding glycoprotein in vivo.
- compositions are formulated to safely pass through the gastric environment.
- Formulations can additionally comprise an excipient, which, as used herein, includes any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, and the like, as suited to the particular dosage form desired.
- Remington s The Science and Practice of Pharmacy, 21st Edition, A. R. Gennaro (Lippincott, Williams & Wilkins, Baltimore, MD, 2006; incorporated herein by reference in its entirety) discloses various excipients used in preparing formulations and known techniques for the preparation thereof.
- an excipient is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% pure. In some embodiments, an excipient is approved for use in humans and for veterinary use. In some embodiments, an excipient is approved by United States Food and Drug Administration. In some embodiments, an excipient is pharmaceutical grade. In some embodiments, an excipient meets the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia, and/or the International Pharmacopoeia.
- USP United States Pharmacopoeia
- EP European Pharmacopoeia
- British Pharmacopoeia the British Pharmacopoeia
- International Pharmacopoeia International Pharmacopoeia
- Formulations can include excipients, such as without limitation, binders, coating, disintegrants, fillers, diluents, flavors, colors, lubricants, glidants, preservatives, sorbents, sweeteners, conjugated linoleic acid (CLA), gelatin, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, oils, beeswax, purified water, glycerol, any type of oil, including, without limitation, fish oil or soybean oil, or the like.
- excipients such as without limitation, binders, coating, disintegrants, fillers, diluents, flavors, colors, lubricants, glidants, preservatives, sorbents, sweeteners, conjugated linoleic acid (CLA), gelatin, dispersing and/or granulating agents, surface active agents and/or emul
- Formulations can comprise suitable solid or gel phase carriers or excipients.
- suitable solid or gel phase carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as, e.g., polyethylene glycols.
- Exemplary diluents include, but are not limited to, calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, etc., and/or combinations thereof.
- Exemplary granulating and/or dispersing agents include, but are not limited to, potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cationexchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked polyvinylpyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (VEEGUM®), sodium lauryl sulfate, quaternary ammonium compounds, etc., and/or combinations thereof.
- crospovidone cross-linked polyvinylpyrrolidone
- sodium carboxymethyl starch sodium starch
- Exemplary surface active agents and/or emulsifiers include, but are not limited to, natural emulsifiers (e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g., bentonite [aluminum silicate] and VEEGUM® [magnesium aluminum silicate]), long chain amino acid derivatives, high molecular weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g., carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polyethylene, poly
- Exemplary binding agents include, but are not limited to, starch (e.g., cornstarch and starch paste); gelatin; sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol,); natural and synthetic gums (e.g., acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, polyvinylpyrrolidone), magnesium aluminum silicate (Veegum®), and larch arabogalactan); alginates; polyethylene oxide; polyethylene glycol; inorganic calcium salts; silicic acid; polymethacrylates; waxes; water; alcohol
- Exemplary preservatives can include, but are not limited to, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and/or other preservatives. Preservatives can be used to prevent spoilage from bacteria, molds, fungi, or yeast (antimicrobials); slow or prevent changes in color, flavor, or texture and delay rancidity (antioxidants); and/or maintain freshness.
- antimicrobial preservatives include, but are not limited to, benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and/or thimerosal.
- Exemplary antifungal preservatives include, but are not limited to, butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and/or sorbic acid.
- Exemplary alcohol preservatives include, but are not limited to, ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and/or phenylethyl alcohol.
- Exemplary acidic preservatives include, but are not limited to, vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and/or phytic acid.
- preservatives include, but are not limited to, tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluened (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, GLYDANT PLUS®, PHENONIP®, methylparaben, GERMALL®115, GERMABEN®II, NEOLONETM , KATHONTM , and/or EUXYL®.
- Exemplary buffering agents include, but are not limited to, citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, is
- oils include, but are not limited to, almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, chamomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana
- oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and/or combinations thereof.
- the formulations can include almond butter, acorn butter, cashew butter, hazelnut butter, macadamia nut butter, peanut butter, pecan butter, pistachio butter, walnut butter, pumpkin seed butter, sesame seed butter (tahini), soybean butter, and/or sunflower seed butter.
- the formulation can include about 5- 25% almond butter.
- the formulations can include sweeteners. These can be used to add sweetness with or without the extra calories.
- sweeteners include sucrose (sugar), glucose, fructose, sorbitol, mannitol, corn syrup, high fructose com syrup, saccharin, aspartame, sucralose, acesulfame potassium (acesulfame-K), and/or neotame.
- the formulations can include color additives. These can be used to offset color loss due to exposure to light, air, temperature extremes, moisture and storage conditions; correct natural variations in color; enhance colors that occur naturally; and/or to provide color to colorless foods.
- color additives include FD&C Blue Nos. 1 and 2, FD&C Green No. 3, FD&C Red Nos. 3 and 40, FD&C Yellow Nos. 5 and 6, Orange B, Citrus Red No. 2, annatto extract, beta-carotene, grape skin extract, cochineal extract or carmine, paprika oleoresin, caramel color, fruit and vegetable juices, and/or saffron.
- the formulations can be dark orange to brown in color.
- the formulations can include flavors and spices. These can be used to add specific flavors (natural and synthetic). Nonlimiting examples include natural flavoring, artificial flavor, and spices e.g., orange, cinnamon, vanillin, vanilla extract, mango extract, cinnamon, citrus, coconut, ginger, viridiflorol, almond, menthol (including menthol without mint), grape skin extract, and/or grape seed extract.
- the formulations can include flavor enhancers. These can be used to enhance flavors already present in foods (without providing their own separate flavor).
- flavor enhancers include monosodium glutamate (MSG), hydrolyzed soy protein, autolyzed yeast extract, disodium guanylate or inosinate.
- the formulations can include nutrients. These can be used to replace vitamins and minerals lost in processing (enrichment), add nutrients that can be lacking in the diet (fortification).
- nutrients include thiamine hydrochloride, riboflavin (Vitamin B2), niacin, niacinamide, folate or folic acid, beta carotene, potassium iodide, iron or ferrous sulfate, alpha tocopherols, ascorbic acid, Vitamin D, amino acids (L-tryptophan, L-lysine, L-leucine, L-methionine).
- the formulations can include stabilizers and thickeners, binders, and/or texturizers. These can be used to produce uniform texture, improve "mouthfeel.”
- Non-limiting examples include gelatin, pectin, guar gum, carrageenan, xanthan gum, whey.
- the formulations can include pH control agents and acidulants. These can be used to control acidity and alkalinity, prevent spoilage.
- Nonlimiting examples include lactic acid, citric acid, ammonium hydroxide, or sodium carbonate.
- the formulations can include humectants. These can be used to retain moisture.
- humectants include glycerin, or sorbitol.
- the formulations of the disclosure can include gelling ingredients such as, but not limited to gelatin, alginate, carageenan, gum, pectin, konjac, agar, food acid, rennet, starch, starch derivatives, and/or combinations thereof.
- gelling ingredients such as, but not limited to gelatin, alginate, carageenan, gum, pectin, konjac, agar, food acid, rennet, starch, starch derivatives, and/or combinations thereof.
- the formulations described herein can include one or more of natural almond butter, glycerin, medium chain triglycerides (MCT oil), oleic acid (from olive oil), phosphatidylcholine, natural clove oil, orange oil, cinnamon oil, vitamin E (as D alpha tocopherol), milk and/or vanilla bean extract.
- MCT oil medium chain triglycerides
- oleic acid from olive oil
- phosphatidylcholine from olive oil
- natural clove oil orange oil
- cinnamon oil as D alpha tocopherol
- milk and/or vanilla bean extract can include one or more of natural almond butter, glycerin, medium chain triglycerides (MCT oil), oleic acid (from olive oil), phosphatidylcholine, natural clove oil, orange oil, cinnamon oil, vitamin E (as D alpha tocopherol), milk and/or vanilla bean extract.
- the formulation used can be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions or the like, preferably in forms of unit dosage suitable for individual administration of precise dosages.
- the formulation can be in the form of a gel, a tablet, a capsule, a liquid, an aerosol, a powder, an effervescent tablet or powder, a syrup, an emulsion, a suspension, a solution, or any other form for providing the formulation to a subject.
- the formulation can be in a form for oral administration, buccal administration, sublingual administration, or any other route of administration as known in the art.
- the nitrogen gas is utilized to remove oxygen from the formulation prior to packaging.
- the formulations of the disclosure are prepared as liposomes.
- a liposome is a microscopic structure made of one or more layers of phospholipid materials resembling the phospholipid that make up cell membranes.
- the outer portion of the liposome can be fat soluble, while the inner portion of the liposome can be water-soluble.
- Liposomes can include lipids having two hydrocarbon chains, typically acyl chains, and a head group, either polar or nonpolar.
- the hydrocarbon chains can be saturated or have varying degrees of unsaturation.
- the two hydrocarbon chains of the lipid can be symmetrical or asymmetrical.
- the acyl chains of the lipids can be saturated or unsaturated.
- Non limiting examples of saturated acyl groups include, trianoic, tetranoic, pentanoic, hexanoic, heptanoic, octanoic, nonanoic, decanoic, undecanoic, dodecanoic, tridecanoic, tetradecanoic, pentadecanoic, hexadecanoic, 3,7,11 ,15-tetramethylhexadecanoic, heptadecanoic, octadecanoic, nonadecanoic, eicosanoic, heneicosanoic, docosanoic, trocosanoic and tetracosanoic.
- Non-limiting examples of unsaturated acyl groups include 9- cis-tetradecanoic, 9-cis-hexadecanoic, 9-cis-octadecanoic, 9-trans-octadecanoic, 9-cis-12- cis-octadecadienoic, 9-cis-12-cis-15-cis-octadecatrienoic, 11-cis-eicosenoic and 5-cis-8-cis- 11 -cis-14-cis-eicosatetraenoic.
- Liposomes can include lipids, such as, but not limited to, sphingolipids, ether lipids, sterols, phospholipids, particularly the phosphoglycerides, and the glycolipids, such as the cerebrosides and/or gangliosides.
- lipids such as, but not limited to, sphingolipids, ether lipids, sterols, phospholipids, particularly the phosphoglycerides, and the glycolipids, such as the cerebrosides and/or gangliosides.
- the liposomes can contain phosphoglycerides.
- Phosphoglycerides include phospholipids such as phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid, phosphatidylinositol, phosphatidylserine phosphatidylglycerol and diphosphatidylglycerol (cardiolipin), where the two hydrocarbon chains are typically between about 14-22 carbon atoms in length and have varying degrees of unsaturation.
- the liposomes can contain phosphatidylcholines.
- exemplary phosphatidylcholines include dilauroyl phophatidylcholine, dimyristoylphophatidylcholine, dipalmitoylphophatidylcholine, distearoylphophatidyl-choline, diarachidoylphophatidylcholine, dioleoylphophatidylcholine, dilinoleoyl-phophatidylcholine, dierucoylphophatidylcholine, palmitoyl-oleoyl-phophatidylcholine, egg phosphatidylcholine, myristoyl-palmitoylphosphatidylcholine, palmitoyl-myristoyl-phosphatidylcholine, myristoylstearoylphosphatidylcholine, palmi
- Asymmetric phosphatidylcholines are referred to as 1-acyl, 2-acyl-sn-glycero-3-phosphocholines, wherein the acyl groups are different from each other.
- Symmetric phosphatidylcholines are referred to as 1,2-diacyl-sn-glycero-3-phosphocholines.
- PC refers to phosphatidylcholine.
- the phosphatidylcholine 1 ,2-dimyristoyl-sn-glycero-3- phosphocholine is abbreviated herein as “DMPC.”
- the phosphatidylcholine 1 ,2-dioleoyl-sn- glycero-3-phosphocholine is abbreviated herein as “DOPC.”
- the phosphatidylcholine 1 ,2- dipalmitoyl-sn-glycero-3-phosphocholine is abbreviated herein as “DPPC.”
- Liposomes can include “caged” phospholipids.
- Caged phospholipids are amino phospholipids that when present in a liposome, render the liposome pH-sensitive so that once endocytosed into target cells the caging groups are cleaved. This cleavage results in destabilization of the liposome, causing the uncaged lipids of the liposome to become fusogenic and to thereby release of the active agent (e.g., compositions described herein) carried by the liposome into the cell.
- the liposomes can contain phosphatidylethanolamines.
- Exemplary phosphatidylethanolamines include dimyristoyl-phosphatidylethanolamine, dipalmitoyl-phosphatidylethanolamine, distearoyl-phosphatidylethanolamine, dioleoylphosphatidylethanolamine and egg phosphatidylethanolamine.
- the liposomes can contain phosphatidic acids.
- exemplary phosphatidic acids include dimyristoyl phosphatidic acid, dipalmitoyl phosphatidic acid and dioleoyl phosphatidic acid.
- the liposomes can contain phosphatidylserines.
- exemplary phosphatidylserines include dimyristoyl phosphatidylserine, dipalmitoyl phosphatidylserine, dioleoylphosphatidylserine, distearoyl phosphatidylserine, palmitoyl-oleylphosphatidylserine and brain phosphatidylserine.
- the liposomes can contain phosphatidylglycerols.
- exemplary phosphatidylglycerols include dilauryloylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, distearoylphosphatidylglycerol, dioleoyl- phosphatidylglycerol, dimyristoylphosphatidylglycerol, palmitoyl-oleoyl-phosphatidylglycerol and egg phosphatidylglycerol.
- the phosphatidylglycerol 1 ,2-dimyristoyl-sn-glycero-3- [phospho-rac-(1 -glycerol)] is abbreviated herein as “DMPG”.
- the phosphatidylglycerol 1 ,2- dipalmitoyl-sn-glycero-3-(phospho-rac-1 -glycerol) (sodium salt) is abbreviated herein as “DPPG”.
- the liposomes can contain sphingomyelins.
- Suitable sphingomyelins can include brain sphingomyelin, egg sphingomyelin, dipalmitoyl sphingomyelin, and distearoyl sphingomyelin.
- lipids for use in liposomes include glycolipids, sphingolipids, ether lipids, glycolipids such as the cerebrosides and gangliosides, and sterols, such as cholesterol or ergosterol.
- the overall surface charge of the liposome can affect the tissue uptake of a liposome.
- anionic phospholipids such as phosphatidylserine, phosphatidylinositol, phosphatidic acid, and cardiolipin are used
- liposome can include neutral lipids such as dioleoylphosphatidyl ethanolamine (DOPE).
- DOPE dioleoylphosphatidyl ethanolamine
- cationic lipids can contain a lipophilic moiety, such as a sterol, an acyl or diacyl chain, and where the lipid has an overall net positive charge.
- Liposomes containing formulations of the disclosure having a more rigid lipid bilayer, or a liquid crystalline bilayer are achieved by incorporation of a relatively rigid lipid.
- the rigidity of the lipid bilayer correlates with the phase transition temperature of the lipids present in the bilayer.
- Phase transition temperature is the temperature at which the lipid changes physical state and shifts from an ordered gel phase to a disordered liquid crystalline phase.
- Several factors affect the phase transition temperature of a lipid including hydrocarbon chain length and degree of unsaturation, charge and headgroup species of the lipid.
- Lipid having a relatively high phase transition temperature can be used to produce a more rigid bilayer.
- Other lipid components, such as cholesterol, are also known to contribute to membrane rigidity in lipid bilayer structures.
- the liposomes can be hollow microspheres of different sizes, ranging from 50nm to 1000nm, made up of one or more lipid bilayers that enclose a hydrophilic core.
- hydrophilic core can include glutathione (GSH), pyrroloquinoline quinone, and/or iron binding glycoprotein.
- the CoQ10 of the composition can be associated with a hydrophobic portion of the liposomes, e.g., the hydrophobic tails of lipids making up the liposomes, a lipid bilayer of the liposomes, or a lipid membrane of the liposomes.
- Liposomes can be classified according to their size and number of lipid bilayers. Liposomes can be multilamellar liposome vesicles: they have an onion-like structure in which various lipid bilayers are intercalated with hydrophilic layers; unilamellar liposomes vesicles formed by a single lipid bilayer and enclose a strongly hydrophilic nucleus or oligolamellar vesicles, made up of several lipid bilayers that enclose a markedly hydrophobic environment. [0100] In one embodiment, the liposomes, can be, multilamellar vesicles (MLV), microemulsified liposomes (MEL), or large unilamellar vesicles (LUVET).
- MLV multilamellar vesicles
- MEL microemulsified liposomes
- LVET large unilamellar vesicles
- the liposomes can have a length or diameter of about 1 - 10 nm, 5 - 15 nm, 10 - 20 nm, 15 - 25 nm, 20 - 30 nm, 25 - 35 nm, 30 - 40 nm, 35 - 45 nm, 40 - 50 nm, 45 - 55 nm, 50 - 60 nm, 55 - 65 nm, 60 - 70 nm, 65 - 75 nm, 70 - 80 nm, 75 - 85 nm, 80 - 90 nm, 85 - 95 nm, 90 - 100 nm, 100 - 200 nm, 150 - 250 nm, 200 - 300 nm, 250 - 350 nm, 300 - 400 nm, 350 - 450 nm, 400 - 500 nm, 450 - 550 nm, 500 - 600 nm, 550 -
- Liposomes can be prepared by hydrating the lipids, followed by sizing of the particles and removing of the non encapsulated composition. Liposomes can be prepared by passive loading mechanical dispersion methods and/or active loading methods, or any other suitable method. In some embodiments, liposomes are prepared by thin-film hydration method, micro emulsification, sonication, membrane extrusion, freeze thawed method, ether injection method, ethanol injection method, reverse phase evaporation method, dehydration- rehydration, and/or calcium-induced fusion method.
- the liposomes of the disclosure are prepared by passive loading method where the composition is encapsulated by introducing an aqueous phase of a water-soluble components of the composition and/or an organic phase of the lipid-soluble components of the composition, before or at some stage during the preparation of the liposomes.
- the liposomes can be prepared by the thin-film hydration procedure, where liposomes are prepared by dissolving the phospholipids in organic solvents, such as, dichloromethane, chloroform, ethanol, and/or chloroform-methanol mixture.
- organic solvents such as, dichloromethane, chloroform, ethanol, and/or chloroform-methanol mixture.
- a thin and homogeneous lipid film can be formed the solvent is evaporated under vacuum at the temperature: about 45-60 °C. Nitrogen gas can be used to completely remove the residual solvent.
- a solution of distilled water, phosphate buffer, phosphate saline buffer at pH 7.4 and normal saline buffer can be used in hydration step.
- the time for the hydration process can be about 1 hour to 2 hours at a temperature of about 60-70 °C.
- the liposomal suspension can be left overnight at about 4-6 °C.
- the liposomes can be prepared by injection methods.
- the liposomes can be prepared by the ether injection method. This method uses a solution of lipids that can be dissolved in ether and/or diethyl ether/methanol mixture which is slowly injected to an aqueous solution of the composition to be capsulated. The subsequent removal of the organic solvent under reduced pressure can lead to the formation of liposomes.
- the liposomes can be prepared by ethanol injection method wherein the ethanolic lipid solution can be rapidly injected to a vast excess of preheated distilled water or TRIS-HCI buffer.
- the liposomes can be prepared by the sonication method.
- the sonication method is based on size transformation and involves the subsequent sonication of multilamellar vesicles (MLVs) prepared by thin-film hydration method, using sonic energy usually under an inert atmosphere including nitrogen or argon.
- MLVs multilamellar vesicles
- the sonication method enables homogenous dispersion of small vesicles using bath type or probe type sonicator with a potential for greater tissue penetration.
- the bath sonicators can be used for preparation of small unilamellar vesicles (SUVs).
- MLVs can be prepared by thin-film hydration method by repeatedly passing the composition and lipids through filters of polycarbonate membranes.
- the liposomes can be prepared using thin-film hydration method subsequently using an extruder for ten cycles to obtain extruded liposomes with uniform diameters.
- the liposomes can be prepared by reverse-phase evaporation method.
- organic solvents such as diethyl ether/isopropyl ether or mixture of diethyl ether and chloroform (1 :1 v/v) and a mixture of chloroform methanol (2:1 v/v)2 can be used.
- the organic phase can be immiscible with aqueous phase thus an oil/water emulsion can be created.
- Phosphate buffer saline or citric-Na2HPO4 buffer can be added to aqueous phase with aim to improve the efficiency of liposome formulations.
- the formation of liposomes can be allowed by continued rotary evaporation of the organic solvents under vacuum.
- the liposomes can be prepared by the calcium-induced method. This method is based on adding of calcium to SUVs. The formation of multilamellar vesicles is as result of fusion. The addition of ethylenediaminetetraacetic acid (EDTA) to the preparations can result in the formation of large unilamellar vesicles (LUV) liposomes.
- EDTA ethylenediaminetetraacetic acid
- LUV liposomes can be obtained from acidic phospholipids.
- the liposomes can be prepared by the freezing and thawing method.
- the method of freezing and thawing is introduced for increasing the trapped volume of liposomal preparations.
- the freeze-thaw method is dependent on the ionic strength of the medium and the phospholipid concentration. It influences to a physical disruption of lamellar structure leading to formation of unilamellar vesicles. The unilamellar vesicles are rapidly frozen followed by slow thawing, while the freeze and thawing cycles are repeated.
- each dose of the formulation is prepared as liposomes within a gel.
- the gel can include an oil and/or a nut butter.
- Nut butter in the gel can be peanut butter, almond butter, cashew butter, pistachio butter, hazelnut butter, walnut butter, macadamia nut butter, pecan butter, Brazil nut butter, chestnut butter, pine nut butter, coconut butter, or combinations thereof.
- An oil in the gel can be sunflower oil, flaxseed oil, hemp seed oil, olive oil, sesame oil, grapeseed oil, canola oil (from rapeseed plant), corn oil, peanut oil, palm oil, avocado oil, or combinations thereof.
- an oil in the gel can include at least one medium chain triglyceride (MCT) oil.
- MCT oil means a medium chain (6 to 12 carbon) aliphatic fatty acid ester of glycerol.
- the at least one MCT oil can be present from about 10% to about 69%, or from about 10% to about 40%, or from about 10% to about 30%, or from about 10% to about 20%, or from about 10% to about 15%, or from about 20% to about 60%, or from about 30% to about 50%, or from about 40% to about 45%, based on the total weight of the oil in the gel.
- the MCT oil can include saturated medium chain fatty acids, for example, a plurality of saturated medium chain fatty acids.
- the MCTs include a mixture of fatty acids having from 6 to 12 carbon atoms.
- the MCT oil can be derived from a plant such as a fruit or vegetable, for example, a plurality of plants.
- the MCT oil can contain caprylic acid, an 8-carbon saturated FA.
- the MCT oil can contain capric acid, a 10-carbon saturated FA.
- the medium-chain triglycerides can contain a mixture of caprylic acid and capric acid.
- the formulation comprises a gel of sunflower oil, MCT oil and almond butter.
- the amount of sunflower oil in the gel can be 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 35 %, 40 %, 45 %, 50 %, 55 %, 60 %, 65 %, 70 %, 75 %, 80 %, 85 %, 90 %, 95 %, 100%, about 1-10%, 15-25%, 20-30%, 25-35%, 30-40%, 35-45%, 40-50%, 45-55%, 50-60%, 55-65%, 60-70%, 65-75%, 70-80%, 75-85%, 80-90%, 85-95% or more of the gel.
- the amount of MCT oil in the gel can be 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 35 %, 40 %, 45 %, 50 %, 55 %, 60 %, 65 %, 70 %, 75 %, 80 %, 85 %, 90 %, 95 %, 100%, about 1-10%, 15- 25%, 20-30%, 25-35%, 30-40%, 35-45%, 40-50%, 45-55%, 50-60%, 55-65%, 60-70%, 65- 75%, 70-80%, 75-85%, 80-90%, 85-95% or more of the gel.
- the amount of almond butter in the gel can be 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 35 %, 40 %, 45 %, 50 %, 55 %, 60 %, 65 %, 70 %, 75 %, 80 %, 85 %, 90 %, 95 %, 100%, about 1 -10%, 15-25%, 20-30%, 25-35%, 30-40%, 35-45%, 40-50%, 45-55%, 50-60%, 55-65%, 60-70%, 65-75%, 70-80%, 75-85%, 80-90%, 85-95% or more of the gel.
- the formulations can also include a gelling agent such as, but not limited to agar, gellan gum, carrageenan, pectin, and/or gelatin.
- Thickening agents can also be added to formulations to prepare gels.
- Non-limiting examples of thickening agents include far celerane, locust bean gum, guar gum, gum arabic, and/or xanthan gum.
- each dose of the compositions of the disclosure can include glutathione in the amount of from about 0.1 mg/ml to 1 mg/ml, about 0.5 mg/ml to 5 mg/ml, 1 mg/ml to 10 mg/ml, 5 mg/ml to 50 mg/ml, 10 mg/ml to 100 mg/ml, 50 mg/ml to 150 mg/ml, 100 mg/ml to 200 mg/ml, 150 mg/ml to 250 mg/ml, 200 mg/ml to 300 mg/ml, 250 mg/ml to 350 mg/ml, 300 mg/ml to 400 mg/ml, 350 mg/ml to 450 mg/ml, 400 mg/ml to 500 mg/ml, 450 mg/ml to 550 mg/ml, 500 mg/ml to 600 mg/ml, 550 mg/ml to 650 mg/ml, 600 mg/ml to 700 mg/ml, 650 mg/ml to 750 mg/ml
- each dose of the compositions of the disclosure can include CoQ10 in the amount of from about 0.1 mg/ml to 1 mg/ml, about 0.5 mg/ml to 5 mg/ml, 1 mg/ml to 10 mg/ml, 5 mg/ml to 50 mg/ml, 10 mg/ml to 100 mg/ml, 50 mg/ml to 150 mg/ml, 100 mg/ml to 200 mg/ml, 150 mg/ml to 250 mg/ml, 200 mg/ml to 300 mg/ml, 250 mg/ml to 350 mg/ml, 300 mg/ml to 400 mg/ml, 350 mg/ml to 450 mg/ml, 400 mg/ml to 500 mg/ml, 450 mg/ml to 550 mg/ml, 500 mg/ml to 600 mg/ml, 550 mg/ml to 650 mg/ml, 600 mg/ml to 700 mg/ml, 650 mg/ml to 750 mg/ml, 700 mg/m/ml,
- each dose of the compositions of the disclosure can include pyrroloquinoline quinone in the amount of the amount of from about 0.1 mg/ml to 1 mg/ml, about 0.5 mg/ml to 5 mg/ml, 1 mg/ml to 10 mg/ml, 5 mg/ml to 50 mg/ml, 10 mg/ml to 100 mg/ml, 50 mg/ml to 150 mg/ml, 100 mg/ml to 200 mg/ml, 150 mg/ml to 250 mg/ml, 200 mg/ml to 300 mg/ml, 250 mg/ml to 350 mg/ml, 300 mg/ml to 400 mg/ml, 350 mg/ml to 450 mg/ml, 400 mg/ml to 500 mg/ml, 450 mg/ml to 550 mg/ml, 500 mg/ml to 600 mg/ml, 550 mg/ml to 650 mg/ml, 600 mg/ml to 700 mg/ml, 650 mg/ml to 750
- each dose of the compositions of the disclosure can include iron binding glycoprotein in the amount of from about 0.1 mg/ml to 1 mg/ml, about 0.5 mg/ml to 5 mg/ml, 1 mg/ml to 10 mg/ml, 5 mg/ml to 50 mg/ml, 10 mg/ml to 100 mg/ml, 50 mg/ml to 150 mg/ml, 100 mg/ml to 200 mg/ml, 150 mg/ml to 250 mg/ml, 200 mg/ml to 300 mg/ml, 250 mg/ml to 350 mg/ml, 300 mg/ml to 400 mg/ml, 350 mg/ml to 450 mg/ml, 400 mg/ml to 500 mg/ml, 450 mg/ml to 550 mg/ml, 500 mg/ml to 600 mg/ml, 550 mg/ml to 650 mg/ml, 600 mg/ml to 700 mg/ml, 650 mg/ml to 750 mg/ml, 700
- each dose of the formulation is prepared as gel.
- each dose of the gel can have a volume of about 0.5 ml, 1 ml, 1.5 ml, 2 ml, 3 ml, 4 ml, 5 ml, 6 ml, 7 ml, 8 ml, 9 ml, 10 ml, 11 ml, 12 ml, 13 ml, 14 ml, 15 ml, 16 ml, 17 ml, 18 ml, 19 ml, 20 ml or more.
- each dose of the formulation can include glutathione (about 22 mg/ml); CoQ10 (about 22 mg/ml), pyrroloquinoline quinone (about 2 mg/ml) and/or iron binding glycoprotein e.g., lactoferrin (about 7 mg/ml).
- each dose of the formulation can include glutathione (about 275 mg); CoQ10 (about 220 mg), and/or pyrroloquinoline quinone (about 22 mg) in 15 ml of a dose of the formulation.
- each dose is prepared as one or more tablets or capsules.
- the formulation can be taken once daily. In some embodiments, the formulation can be taken twice daily, three times daily, four times daily, or more than four times daily. In one example, the formulation can be taken with meals. In some embodiments, the formulation can be taken immediately following a meal. In some embodiments, the formulation is not mixed with the meal. In some embodiments, the formulation can be taken in the morning, afternoon, evening, and/or night. In one example, the formulation can be taken at the same time every day. In another example, the time the formulation is taken can vary. In one example, the daily intake can be contained in one packaging of the formulation that can be consumed once daily.
- the daily intake can be split across more than one packaging of the formulation which can be taken together.
- the daily intake can be contained in two packages of the formulation and a user can administer two packages of the formulation once daily.
- the daily intake can be contained in three packages and a user can administer three packages once daily or administer one package of the formulation three times daily.
- the daily intake can be contained in four or more packages of the formulation that can be administered one to four times daily.
- the formulations of the disclosure can be administered for 1 day, 1 week, 1 month, 1 year or more. In some embodiments, the formulations can be administered for about 1-30 days, 1 -60 days, 1-90 days, 1-120 days, 1 -150 days or more. In some embodiments, the formulations can be administered for about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 20 days, 30 days, 40 days, 50 days, 60 days, 70 days, 80 days, 90 days, 100 days or more. In some embodiments, the formulations can be administered for 1 week, 2 weeks, 3 weeks, 4 weeks, or more. In some embodiments, the formulations can be administered for 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months or more.
- Formulations of the present disclosure can be administered in the conventional manner by any route where they are active. Administration can be systemic, parenteral, topical, or oral. As a non-limiting example, administration is oral. In some embodiments, the administration can be, but is not limited to, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, oral, buccal, or ocular routes, or intravaginally , by inhalation, by depot injections, or by implants.
- compositions of the disclosure can be used by individuals who do not present one or more symptoms associated with a disease, condition or a syndrome. In some embodiments, the compositions of the disclosure can be used to treat or improve symptoms associated with one or more diseases, conditions, or syndrome.
- compositions of the disclosure can be used to reduce systemic fatigue, cellular inflammation, and/or reactive oxygen species.
- compositions of the disclosure can be used to increase energy potential of cellular systems by increasing mitochondrial biogenesis.
- compositions of the disclosure can be used to treat diseases or disorders associated with oxidative stress, such as, but not limited to, chronic fatigue syndrome, cardiovascular diseases, diabetes, cancer, chronic kidney disease, chronic obstructive pulmonary disease (COPD), neurological disease.
- diseases or disorders associated with oxidative stress such as, but not limited to, chronic fatigue syndrome, cardiovascular diseases, diabetes, cancer, chronic kidney disease, chronic obstructive pulmonary disease (COPD), neurological disease.
- COPD chronic obstructive pulmonary disease
- the compositions of the disclosure can be used to treat chronic fatigue syndrome and/or major depressive disorder.
- compositions of the disclosure can be used to improve lifespan or healthspan of a subject.
- compositions of the disclosure can be of any age, such as, but not limited to about 1-10 years, 5-15 years, 10-20 years, 15-25 years, 20- 30 years, 25-35 years, 30-40 years, 35-45 years, 40-50 years, 45-55 years, 50-60 years, 55- 65 years, 60-70 years, 65-75 years, 70-80 years or more.
- compositions of the disclosure can prevent the occurrence of a disease.
- preventing or ‘prevention’ refers to a reduction in risk of acquiring or developing a disease or disorder (i.e. , causing at least one of the clinical symptoms of the disease not to develop) in a subject that can be exposed to a disease-causing agent, or predisposed to the disease in advance of disease onset.
- compositions of the disclosure can be used to treat Chronic Fatigue Syndrome (CFS).
- CFS can be associated with decreased GSH concentration in the brain and mitochondrial dysfunction can be directly related to CFS and neuroinflammation disorders.
- CFS Chronic fatigue syndrome
- CFS chronic fatigue syndrome
- epidemic neuromyasthesia idiopathic chronic fatigue and myalgia syndrome
- chronic infectious mononucleosis myalgic encephalomyelitis
- post-viral fatigue syndrome or fibrositis-fibromyalgia syndrome.
- the compositions of the disclosure can be used to improve one or more symptoms associated with CFS.
- the compositions of the disclosure can improve one or more symptoms by 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 35 %, 40 %, 45 %, 50 %, 55 %, 60 %, 65 %, 70 %, 75 %, 80 %, 85 %, 90 %, 95 %, 100%, about 1-10%, 15-25%, 20-30%, 25-35%, 30-40%, 35-45%, 40-50%, 45-55%, 50-60%, 55-65%, 60- 70%, 65-75%, 70-80%, 75-85%, 80-90%, 85-95% or more.
- the primary symptom of CFS is fatigue, which has a definite onset, and is severe, disabling and affects both physical and mental functioning, and furthermore the fatigue is present for a minimum of 6 months at which it was present for more than 50 % of the time.
- CFS can include sleep disturbances, which are changes in the duration of sleep and/or quality of sleep.
- the changes could be hypersomnia or increased sleep, or insomnia or reduced sleep, (which should further be described as either difficulty of getting off to sleep, early wakening, or subjectively disturbed or unrefreshing sleep).
- CFS is associated with disability, which, as used herein, can refer to any restriction or lack (resulting from loss of psychological or physiological function) of ability to perform an activity in the manner or within the range considered normal for human being, i.e., things that people cannot do in the areas of occupational, social and leisure activities because of their illness.
- the disability associated with CFS can be distinguished from impairment of function (e.g., weak legs) and from handicap (e.g., unable to work).
- CFS can be associated with Myalgia, which is pain or aching felt in the muscles. The myalgia can be disproportionate to exertion and can be distinguished from feelings of weakness and pain felt in other areas such as the joints.
- individuals with CFS can have problems with thinking and memory. Most people with CFS have trouble thinking quickly, remembering things, and paying attention to details.
- individuals with CFS can have “brain fog” which is generally used to describe the feeling of not being able to think clearly.
- individuals with CFS can have worsening of symptoms while standing or sitting upright. This is called orthostatic intolerance. People with CFS can be lightheaded, dizzy, weak, or faint while standing or sitting up. They can have vision changes like blurring or seeing spots.
- individuals with CFS can have pain (not associated with an injury), muscle pain and aches, joint pain without swelling or redness, headaches, either new or worsening, tender lymph nodes in the neck or armpits, sore throat, digestive issues, like irritable bowel syndrome, chills and night sweats, allergies and sensitivities to foods, odors, chemicals, light, or noise, muscle weakness, shortness of breath, and/or irregular heartbeat.
- PEM post-exertional malaise
- any CFS symptoms can get worse or first appear, including difficulty thinking, problems sleeping, sore throat, headaches, feeling dizzy, or severe tiredness. It may take days, weeks, or longer to recover from a crash. Sometimes patients can be house-bound or even completely bed-bound during crashes.
- compositions of the disclosure can, within about 30 days, cause a reduction of fatigue, reduction in feeling of tiredness, and improve output and recovery during aerobic exercise.
- compositions of the disclosure can, within about 60 days can result in quicker recall, stronger attention span during tasks, deeper and more restorative sleep, reduction in inflammatory markers within the body in patients with CFS.
- compositions of the disclosure can, within about 90 days, increase energy, alertness and activity levels, decrease creatine kinase activity and myoglobin concentration in those with exercise-induced muscle damage
- the compositions of the disclosure can be used to treat diabetes.
- the diabetes can be type 1 diabetes, type 2 diabetes or gestational diabetes.
- Reduced GSH have been associated with insulin resistance associated with type 2 diabetes.
- Insulin resistance can refer to the reduced or inability of the cells, tissue or organisms to take up glucose in the presence of insulin.
- the compositions of the disclosure can reduce insulin resistance by 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 35 %, 40 %, 45 %, 50 %, 55 %, 60 %, 65 %, 70 %, 75 %, 80 %, 85 %, 90 %, 95 %, 100%, about 1- 10%, 15-25%, 20-30%, 25-35%, 30-40%, 35-45%, 40-50%, 45-55%, 50-60%, 55-65%, 60- 70%, 65-75%, 70-80%, 75-85%, 80-90%, 85-95% or more.
- compositions of the disclosure can be used to improve one or more symptoms associated with diabetes including, but not limited to, fatigue, increase urination, thirst, weight loss, hunger, blurry vision, numb or tingling hands and/or feet, increase infections or delayed wound healing.
- compositions of the disclosure can be used to treat a subject diagnosed with major depressive disorder (MDD).
- MDD is a mood disorder that can cause a persistent feeling of sadness and loss of interest.
- Patients with MDD have shown to have pro-inflammatory cytokines (IL-6, IL-8) as well as acute and chronic mitochondrial dysfunction.
- compositions of the disclosure can be used improve one or more symptoms associated with MDD, such as, but not limited to feelings of sadness, tearfulness, emptiness or hopelessness, angry outbursts, irritability or frustration, even over small matters, loss of interest or pleasure in most or all normal activities, such as sex, hobbies or sports, sleep disturbances, including insomnia or sleeping too much, tiredness and lack of energy, so even small tasks take extra effort, reduced appetite and weight loss or increased cravings for food and weight gain, anxiety, agitation or restlessness, slowed thinking, speaking or body movements, feelings of worthlessness or guilt, fixating on past failures or self-blame, trouble thinking, concentrating, making decisions and remembering things, frequent or recurrent thoughts of death, suicidal thoughts, suicide attempts or suicide, unexplained physical problems, such as back pain or headaches.
- symptoms associated with MDD such as, but not limited to feelings of sadness, tearfulness, emptiness or hopelessness, angry outbursts, irritability or frustration, even over small matters
- the compositions of the disclosure can improve one or more symptoms of MDD symptoms by about 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 35 %, 40 %, 45 %, 50 %, 55 %, 60 %, 65 %, 70 %, 75 %, 80 %, 85 %, 90 %, 95 %, 100%, about 1- 10%, 15-25%, 20-30%, 25-35%, 30-40%, 35-45%, 40-50%, 45-55%, 50-60%, 55-65%, 60- 70%, 65-75%, 70-80%, 75-85%, 80-90%, 85-95% or more.
- compositions of the disclosure provide for increasing or improving healthspan of a subject.
- healthspan can be defined as the period of life spent free of age- related diseases/conditions.
- the healthspan of a given subject can therefore refer to the period during which the subject does not have an age-related disease/condition (e.g., an age-related disease described herein).
- a subject can be considered to not to have a given disease/condition until they are diagnosed with a relevant disease condition.
- a subject having an improved/increased/extended healthspan can remain free of an age-related disease/condition for a longer period as compared to a reference subject.
- a subject administered with the compositions of the disclosure can have an increased healthspan as compared to an equivalent, untreated subject.
- the increase in healthspan can be by about 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 35 %, 40 %, 45 %, 50 %, 55 %, 60 %, 65 %, 70 %, 75 %, 80 %, 85 %, 90 %, 95 %, 100%, about 1-10%, 15-25%, 20-30%, 25-35%, 30-40%, 35-45%, 40-50%, 45-55%, 50-60%, 55-65%, 60- 70%, 65-75%, 70-80%, 75-85%, 80-90%, 85-95% or more.
- “healthspan” can also refer to the period of life during which a subject does not exhibit significant age-related deterioration in the function of a tissue, organ or organ system of the subject.
- the deterioration in function can arise as a consequence of an age- related disease/condition.
- a subject displaying deterioration in a function of a given tissue/organ/organ system can display a level of the relevant function which is less than 1 times, e.g.
- the compositions can also be used to extend lifespan.
- lifespan can be defined as the length of time for which a person lives.
- the compositions of the disclosure can increase lifespan by about 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years, 15 years, 20 years, 25 years, 30 years, 35 years, 40 years, 45 years, 50 years, about 1 -2 months, 2-3 months, 3-4 months, 4-5 months, 5-6 months, 6-7 months, 7-8 months, 8-9 months, 9-10 months, 10-11 months, 1 -2 years, 2-3 years, 3-4 years, 4-5 years, 5-6 years, 6-7 years, 7-8 years, 8-9 years, 9-10 years, 10-20 years, 15-25 years, 20-30 years, 25-35 years, 30-40 years, 35-45 years, 40-50 years or more.
- compositions and methods are more particularly described below, and the Examples set forth herein are intended as illustrative only, as numerous modifications and variations therein will be apparent to those skilled in the art.
- the terms used in the specification generally have their ordinary meanings in the art, within the context of the compositions and methods described herein, and in the specific context where each term is used. Some terms have been more specifically defined herein to provide additional guidance to the practitioner regarding the description of the compositions and methods.
- the term “and/or” includes any and all combinations of one or more of the associated listed items.
- the meaning of “a”, “an”, and “the” includes plural reference as well as the singular reference unless the context clearly dictates otherwise.
- the term “about” in association with a numerical value means that the value varies up or down by 5%. For example, for a value of about 100, means 95 to 105 (or any value between 95 and 105).
- compositions and methods are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the compositions and methods are also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.
- compositions and methods are also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.
- ROS Reactive oxygen species
- Liquid culture medium is prepared as follows: S medium, 50 uM 5- Fluorodeoxyuridine (FUdR), 200 pg/ml Streptomycin, and filtered OP50.
- the L4 animals are resuspended in liquid culture at about 2 animals/pl. 90pl of the animals in the liquid culture media are added to each well.
- Compositions of the disclosure are extracted into ethanol, water and/or DMSO and 10 pl are added to each well. Micro plates are sealed and incubated at 20°C overnight on shaker.
- ROS assay is expected to show that pre-treatment with the compositions of the disclosure can provide improved protection against reactive oxygen species (ROS) than the positive control, paraquat.
- ROS reactive oxygen species
- the lifespan assay is initiated by expanding all groups (group treated with compositions of the disclosure and control group) to more than 1000 animals, then synchronizing by bleaching and allowing larval animals to hatch and arrest. To eliminate the effect of bacterial metabolism and growth on lifespan, synchronized animals are only exposed to dead food bacteria. To suppress progeny, animals are transferred to media containing 5-Fluorodeoxyuridine (FUdR) within 54-60 hours post-plating. Animals are inspected 24 and 48 hours after this transfer to confirm infertility. Finally, the animals are inspected for general health and morphology before transferring to scanner plates. The scanner plates are incubated for an additional 2 days and inspected again before loading onto scanners.
- FUdR 5-Fluorodeoxyuridine
- lifespan data is collected using an Automated Lifespan Machine (ALM) which is adapted from Stroustrup, N.
- ALM Automated Lifespan Machine
- Time of death calls exported from the ALM software is analyzed and plotted using the Lifelines software package developed by Cam Davidson-Pilon et al., CamDavidsonPilon/lifelines: vO.25.9 (https://doi.org/10.5281/zenodo.4505728; the contents of which are herein incorporated by reference in its entirety). Additional analysis is performed using the OASIS2 analysis software. A standard Mantel-Cox log-rank test is used to compare the curves globally over the course of the lifespan assigning equal weight to each timepoint, whereas the Wilcoxon-Breslow-Gehan weights each death by the number of subjects at risk, assigning greater weight to earlier deaths. Each of these tests is expected to show a significant increase in survival upon treatment with the compositions of the disclosure compared to the control. [0166] The survival rate is expected to increase significantly in animals treated with the compositions of the disclosure compared to untreated controls.
- Worm movement is tracked from the images acquired by the ALM during the lifespan assay. Worm size and movement features are extracted and analyzed using custom software. Worm Activity serves as a proxy for animal health. Changes in spatial distribution of the animals between time points is used to derive gross movement for the population over time. Foreground motion is calculated using an approach called difference based spatial temporal entropy image (DSTEI) (see Ma, Yu-Fei et al., In IEEE International Conference on Multimedia and Expo, 2001. ICME 2001., 265-68; the contents of which are herein incorporated by reference in its entirety). Worm morphology is measured from the worm contours detected in the images.
- DSTEI difference based spatial temporal entropy image
- RNA Miniprep Kit More than 150-day 1 adult animals per replicate are harvested, cleaned by filtration, and frozen at -80° in Trizol. To extract RNA, samples are thawed, vigorously vortexed, and processed using the Direct-zol RNA Miniprep Kit (Zymo Research).
- RNA is enriched for poly-mRNA using oligo(dT) paramagnetic beads.
- DNA libraries are then constructed from this input mRNA using the NEBNext UltraTM II RNA Library Prep Kit to create a ready-to-sequence dsDNA library that retains the strand-specific information in the original mRNA. These libraries are then further tested by the Qubit for concentration and the Agilent 2100 for library size distribution and quality. In order to properly pool the libraries and load them onto sequencing lanes to ensure the correct number of reads per sample, an even more precise quantification of the library is done via qPCR, and the samples are loaded onto the NovaSeq 6000 platform for a paired-end sequencing run of 150 bp for each end (PE150).
- the loading concentrations are designed to obtain at least 6.0 Gb (which is the number of billion bases of raw data, determined by the number of reads multiplied by the length of each read).
- DEGs Differentially expressed genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The present disclosure provides compositions containing glutathione, coenzyme Q10 (CoQ10), pyrroloquinoline quinone, and/or iron binding glycoproteins. Formulations comprising the compositions described herein are also provided. Methods of use of the compositions including methods of treatment of disease such as chronic fatigue syndrome, diabetes and other indications are also provided herein.
Description
GLUTATHIONE COMPOSITIONS AND METHODS OF USE
PRIORITY
[0001 ] This application claims benefit of priority to U.S. Provisional Application No: 63/264,909 filed on December 03, 2021 , the contents of which are herein incorporated by reference in their entirety.
BACKGROUND
[0002] Many consequences of increased chronological age can be broadly attributed to an organism’s inability to maintain homeostasis at the cellular and organism level. Adaptive homeostasis is a phenomenon, shared across cells and tissues of both simple and complex organisms, that enables the expansion or contraction of the homeostatic range to modulate stress-protective systems in response to varying internal and external environments. As organisms age, the homeostasis can be disrupted due to an imbalance in the stress and stress protective mechanisms. This dysregulation of adaptive homeostasis in the final third of lifespan is a factor in the ageing process and stress associated disease, while successful maintenance or restoration of adaptive homeostasis can result in extended, healthy longevity.
SUMMARY
[0003] The present disclosure provides compositions and methods for use in treating a subject. In some embodiments the compositions can include glutathione, coenzyme Q10 (CoQ10), pyrroloquinoline quinone, iron binding glycoprotein or any combination thereof. In some embodiments, the concentration of glutathione can be about 10 mg/ml to 100 mg/ml. In some embodiments, the concentration of glutathione can be about 22 mg/ml. In some
embodiments, the concentration of CoQ10 can be about 10 mg/ml to 100 mg/ml. In some embodiments, the concentration of CoQ10 can be about 22 mg/ml. In some embodiments, the concentration of pyrroloquinoline quinone can be about 1 mg to 10 mg. In some embodiments, the concentration of pyrroloquinoline quinone can be about 2 mg/ml. In some embodiments, the iron binding glycoprotein can be lactoferrin or transferrin. As a non-limiting example, the iron binding glycoprotein can be lactoferrin. In one embodiment, lactoferrin is a bovine lactoferrin. The concentration of bovine lactoferrin can be about 5 mg/ml to 50 mg/ml. In some embodiments, the concentration of bovine lactoferrin can be about 7 mg/ml.
[0004] Also provided herein are formulations comprising the compositions and at least one excipient. The excipient can be glycerin, oleic acid (from olive oil), natural clove oil, orange oil, cinnamon oil, vitamin E, milk and/or vanilla bean extract. In some embodiments, the formulation can be prepared as a liposome.
[0005] In some embodiments, the liposomes can include phosphatidylcholine. In some embodiments, the formulations can be present within a gel. The gel can include nut butter and/or an oil. The nut butter can be almond butter. In some embodiments, the oil can be medium chain triglyceride (MCT) oil and/or sunflower oil. As a non-limiting example, a gel can include almond butter, MCT oil and/or sunflower oil.
[0006] The present disclosure also provides methods of use. In some embodiments, the compositions can be used to treat Chronic Fatigue Syndrome (CFS). In some embodiments, the compositions can improve one or more symptoms associated with CFS. In some embodiments, the composition can be administered for about 50-150 days, for example, for about 30 days, 60 days, 90 days or more. Methods of treatment of diseases such as, but not limited to, cardiovascular diseases, diabetes, cancer, chronic kidney disease, chronic obstructive pulmonary disease (COPD), and/or neurological diseases are also provided herein.
[0007] The present disclosure also provides a method of increasing healthspan or lifespan in a subject by administering the compositions of the disclosure.
BRIEF DESCRIPTION OF THE DRAWINGS
[0008] Various objectives, features, and advantages of the disclosed subject matter can be more fully appreciated with reference to the following detailed description of the disclosed
subject matter when considered in connection with the following drawings, in which like reference numerals identify like elements.
[0009] Figure 1 shows adaptive responses in various age groups.
[0010] Figure 2 is an example of the formulation of the disclosure prepared as a liposome.
DETAILED DESCRIPTION
[0011 ] The details of one or more variations of the subject matter described herein are set forth in the accompanying drawings and the description below. Other features and advantages of the subject matter described herein will be apparent from the description and drawings, and from the claims. The disclosed subject matter is not, however, limited to any particular embodiment disclosed.
Overview
[0012] Reactive oxygen species (ROS) are produced by cells as normal cellular metabolic byproducts. Environmental toxins, age, stress, pharmaceutical agents, or pre-existing conditions can result in an increase in ROS. Excess reactive oxygen species (ROS) can lead to the destruction of biomolecules, and cellular organelles. Under excessive stress conditions, cells can produce numerous ROS, and the living organisms eventually evolve a series of response mechanisms to adapt to the ROS exposure as well as utilize it as the signaling molecules. ROS molecules can also trigger oxidative stress in a feedback mechanism involving many biological processes, such as apoptosis, necrosis and autophagy. Furthermore, ROS can play a role as the signaling molecules in the cell death pathway. Overwhelming production of ROS can destroy organelle’s structure and biomolecules, which also leads to inflammatory responses. Oxidative damage ensues when the generation of free radicals and reactive oxygen and nitrogen species exceeds the capacity of cellular defense mechanisms.
[0013] Organisms are equipped with mechanisms to combat ROS. As organisms age, there an imbalance between the systemic manifestation of ROS and the organism’s ability to readily detoxify ROS or to repair the resulting damage. This imbalance is referred to as oxidative stress. Mitochondria play a critical role in combatting ROS. However, mitochondrial biogenesis declines with age due to alterations in mitochondrial dynamics and inhibition of mitophagy, an autophagy process that removes dysfunctional mitochondria. Age-dependent abnormalities in mitochondrial quality control further weaken and impair mitochondrial
function. In addition, with advanced chronological age, antioxidant concentrations in blood can decline leading to an increase in reactive oxygen species (ROS).
[0014] Excess reactive oxygen species (ROS) can lead to the destruction of biomolecules and cellular organelles which lead to chronic age-related conditions such as neurodegenerative diseases, cancer, diabetes, and kidney disease. In the case of neurodegenerative diseases, the nerve cells from brain and spinal cord can suffer from mitochondrial dysfunctions as well as exci to toxicity and finally apoptosis, which lead to either functional loss or sensory dysfunctions. Since the brain has a high metabolic rate and relatively reduced capacity for cellular regeneration, nerve cells in the brain area are particularly susceptible to damage by ROS. Long term, free radicals and oxidative stress can work together to accelerate aging and increase the risk of diseases e.g., fatigue, cancer, inflammatory joint disease, dementia, asthma and diabetes among others. There is a need in the art for compositions that can combat oxidative stress and prevent or reduce the incidence of diseases and conditions associated with increased oxidative stress.
[0015] The present disclosure provides compositions of glutathione (GSH), CoQ10, pyrroloquinoline quinone, and/or iron binding glycoproteins for restoring adaptive homeostasis by up-regulating aging related pathways and related gene expressions. In some embodiments, the compositions of the disclosure can reduce or prevent the decline of biological homeostasis and adaptability by upregulating detoxification pathways such as mitophagy, autophagy and ROS and down regulating mTOR, insulin and AMPK, while increasing the density and number of mitochondria and increasing the efficiency of their electron transport.
Glutathione
[0016] In some embodiments, the compositions of the disclosure can include glutathione In some embodiments, the glutathione is reduced glutathione (GSH). In the present disclosure the terms glutathione and reduced glutathione can be used interchangeably and are used to indicate the reduced form, GSH. Glutathione is a fundamental antioxidant that reduces ROS within the body, protecting cells and preventing tissue damage.
[0017] Glutathione (GSH) is an abundant antioxidant and a major detoxification agent in cells. In some embodiments, GSH can be synthesized by the sequential addition of the precursor amino acids, cysteine (Cys), glutamic acid (Glu) and glycine (Gly) through two- enzyme reactions catalyzed by glutamate cysteine ligase and glutathione synthetase. GSH
levels are regulated in response to redox change. It plays a role in cell growth, proliferation, apoptosis and signaling, particularly redox signaling. GSH acts as an antioxidant in two ways, it directly reacts non-enzymatically with free radicals such as superoxide radical (O2"), NO, or hydroxyl ion (OH") and it indirectly functions as a reducing agent by donating an electron to H2O2 for its reduction to water and O2 in the presence of glutathione peroxidase (GPx) enzyme. Due to its potential cytoprotective functions there has been great interest in increasing GSH via analogs and precursors. Accordingly, GSH can play a role in protecting neuronal tissue, pulmonary cells and cardiovascular structures by enhancing GSH-related detoxification capacity.
[0018] Low GSH levels can impair immune function. GSH is also involved in the maintenance of optimal cytokine levels. GSH depletion can lead to an increase in pro- inflammatory cytokines i.e., tumor necrosis factor-a (TNF-a), lnterleukin-1 p (IL-1 p) and IL-6 gene expression but may not affect levels of anti-inflammatory cytokines such as IL-10. Low levels of GSH can be associated with exposure to oxidants/drugs/toxins, poor nutrition and other factors. GSH levels are also dependent on the availability of its precursor amino acids, Cys, Glu and Gly, with Cys most often considered as rate limiting. Mouse models have suggested that intracellular GSH levels can be depleted in certain tissues, including the liver, by short periods of fasting such as that which occurs overnight. Additionally, GSH is the most abundant brain antioxidant and altered GSH can be a key aspect of the pathogenesis of mild cognitive impairment, many neurological disorders and Alzheimer’s disease. Furthermore, higher GSH levels have been identified in the brains of older adults compared to their younger counterparts, suggesting that the higher GSH levels are present to help offset the age-related increases in oxidative stress and therefore maintain redox homeostasis.
CoQ10
[0019] In some embodiments, compositions of the disclosure can include CoQ10. CoQ10 can improve the speed and efficiency of mitochondria facilitating more energy transfer and energy availability at a cellular level.
[0020] Coenzyme Q10 (CoQ10), also known as ubiquinone, is a lipid-soluble vitamin-like compound. CoQ10 is present in the inner membrane of the mitochondria of the cell. High levels of CoQ10 is found in high energy cells such as heart, brain, liver, and kidney cells. In the aging process, cellular production of CoQ10 decreases.
[0021 ] There are at least two functions of CoQ10. First, CoQ10 acts as a regenerating antioxidant, helping to quench free radicals and prevent lipid peroxidation. Second, CoQ10 is a mitochondrial energy coupler, which is part of the cellular process for synthesizing adenosine triphosphate (ATP), the body’s main source of energy.
[0022] By facilitating ATP synthesis in the mitochondria and upregulating mitochondrial function, CoQ10 can also support cognitive function. CoQIO’s antioxidant activity also has neuroprotective effects by protecting against oxidative stress in the mitochondria of brain cells. CoQ10 can also attenuate oxidative damage in the mitochondria to reduce cognitive effects associated with normal brain aging, and to supplement spatial learning.
[0023] CoQ10 can decrease hepatic mRNA expression of IL-6 and TNF-a, to attenuate the level of C-reactive protein (CRP) in rodent models. CoQ10 supplementation with doses ranging from about 100-500 mg/day can increase the serum level of CoQ10, and decrease TNF-a, but no substantial difference is observed in CRP.
[0024] CoQ10 oral administration can provide beneficial effects on a range of different disorders that have been associated with low CoQ10 levels and high oxidative stress, such as, but not limited to, mitochondrial, cardiovascular, and neurodegenerative diseases.
Pyrroloquinoline quinone
[0025] In some embodiments, compositions of the disclosure can include pyrroloquinoline quinone (PQQ), an aromatic tricyclic o-quinone that serves as a redox cofactor of a number of prokaryotic dehydrogenases, such as alcohol and sugar dehydrogenases. PQQ can exert pro-oxidant actions by the formation of reactive oxygen species (ROS), such as O2- and H2O2, via its redox cycling under certain conditions. PQQ can influence energy-related metabolism and neurologic functions in animals. The mechanism of action involves interactions with cell signaling pathways and mitochondrial function. PQQ has anti-oxidative and mitochondrial biogenesis capacities. Reduced PQQ can provide strong antioxidant capacity. In some embodiments, the antioxidant capacity can be greater than ascorbic acid, by about 2 times, 3 times, 4 times, 5 times, 6 times, 7, times, 8 times, 9 times or 10 times. As a non-limiting example, the antioxidant capacity of the compositions of the disclosure can be about 7.4 times greater than ascorbic acid. Increasing PQQ levels can trigger the growth of new mitochondria and nerve cells with strong neuroprotective signals.
Iron Binding Glycoprotein
[0026] In some embodiments, the compositions of the disclosure can include iron binding glycoproteins. In some embodiments, the iron binding glycoprotein is used for absorption via the jejunum (the second part of the small intestine).
[0027] The iron binding glycoprotein can be a synthetic iron binding glycoprotein, a recombinant iron binding glycoprotein or a natural iron binding glycoprotein. The iron binding glycoprotein can be derived from any mammal. In some embodiments, the iron binding glycoprotein can be derived from a cow, human, monkey, dog, cat, mouse, rat, guinea pig, and/or hamster.
[0028] In some embodiments, the iron binding glycoprotein can be lactoferrin or transferrin.
[0029] In some embodiments, the iron binding glycoprotein can be lactoferrin. Lactoferrin (LF) is a cationic iron-binding glycoprotein with molecular weight of about 77-80 kDa. Lactoferrin is folded into two globular lobes connected by an a-helical bridge and stabilized by a number of disulfide bonds. The main function of this protein is to control and regulate the concentration of free iron in biological fluids via its ability to either solubilize or sequester ferric ions (Fe3+). LF can be either extracted from milk or produced by recombinant techniques in microorganisms for use in the compositions of the disclosure. Generally, one LF molecule can typically binds two Fe3+ ions, which greatly depends on the synergistic binding of two HCOs " or CO3 2". In vitro iron release can be enhanced from LF molecule by lowering the pH or using chelating agents. Moreover, structure analysis of LF revealed that it is composed of 2 lobes. Each lobe includes 2 domains separated by a cleft that can cobind Fe3+ and CO3 2". The binding and the release of substrates is usually associated with conformational changes including opening and closing of the interdomain cleft. Two carbohydrate attachment sites are present on the LF molecule, one in each lobe. The first [3- a-p unit (residues 1 to 40) includes about nine basic sidechains protruding from the surface (most near the C terminus of helix A) which seems to be a receptor binding moiety, responsible for receptor recognition of LF.
[0030] In some embodiments, lactoferrin can be bovine lactoferrin (UniProt ID: Q6LBN7). [0031 ] In some embodiments, the lactoferrin can be ENSEMBL translation ID ENSP00000231751.4, ENSP00000395234.1 , ENSP00000397427.1 , ENSP00000405546.1 , ENSP00000405719.2, ENSP00000508000.1 , a portion, or a variant thereof.
[0032] As a non-limiting example, the iron binding glycoprotein can be transferrin. Presence of transferrin in the compositions can allow the safe transfer of the compositions through the gastric environment. Human transferrin is a single-chain glycoprotein. It has two potential N-linked glycosylation sites and one potential O-linked glycosylation site. Transferrin binds two Fe3+ ions, with high affinity (Kd ~ 10-20 M), together with two synergistically bound COs2- ions. The protein is mainly synthesized in the liver and secreted into the plasma. Lower amounts are also produced in other organs, such as the testis and brain. Transferrin can also act as a cytokine. For example, transferrin has been identified as one of the factors that promote the clonal growth of the precursors of murine granulocytes and macrophages cultured in vitro under serum-free conditions. In some embodiments, the compositions of the disclosure can include the entire transferrin protein or a fragment thereof. In some embodiments, the transferrin can be ENSEMBL Translation ID ENSP00000385834.3, ENSP00000419338.1 , ENSP00000417468.1 , a portion thereof or a variant thereof. Physiologically, transferrin is responsible for the transport of iron and controls the level of iron in biological fluids. Transferrin-receptors (TfR) on cell surfaces, can bind Tf with high affinity and internalize into the cell. Transferrin receptor (TfR) can also transport transferrin across the blood-brain barrier (BBB), which can be exploited to deliver the compositions of the disclosure from the bloodstream into the brain.
[0033] In some embodiments, transferrin can be bovine transferrin or human transferrin. [0034] In some aspects an iron binding protein can be covalently or non-covalently linked to glutathione, coenzyme Q10 (CoQ10), pyrroloquinoline quinone, or combinations thereof. Compositions
[0035] Compositions of the disclosure can include a combination comprising one or more of glutathione, CoQ10, pyrroloquinoline quinone and/or iron binding glycoprotein. Compositions can be prepared in an oxygen deprived environment to prevent oxidation of the composition.
[0036] In some embodiments, the compositions can include glutathione in the amount of from about 0.1 mg to 1 mg, about 0.5 mg to 5 mg, 1 mg to 10 mg, 5 mg to 50 mg, 10 mg to 100 mg, 50 mg to 150 mg, 100 mg to 200 mg, 150 mg to 250 mg, 200 mg to 300 mg, 250 mg to 350 mg, 300 mg to 400 mg, 350 mg to 450 mg, 400 mg to 500 mg, 450 mg to 550 mg, 500 mg to 600 mg, 550 mg to 650 mg, 600 mg to 700 mg, 650 mg to 750 mg, 700 mg to 800 mg, 850 mg to 950 mg, 900 mg to 1000 mg or more.
[0037] In some embodiments, the compositions can include glutathione in the amount of 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, or more. In some embodiments, the compositions can include glutathione in the amount of 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg, or 300 mg.
[0038] In some embodiments, the compositions can include glutathione in the amount of from about 0.1 mg/ml to 1 mg/ml, about 0.5 mg/ml to 5 mg/ml, 1 mg/ml to 10 mg/ml, 5 mg/ml to 50 mg/ml, 10 mg/ml to 100 mg/ml, 50 mg/ml to 150 mg/ml, 100 mg/ml to 200 mg/ml, 150 mg/ml to 250 mg/ml, 200 mg/ml to 300 mg/ml, 250 mg/ml to 350 mg/ml, 300 mg/ml to 400 mg/ml, 350 mg/ml to 450 mg/ml, 400 mg/ml to 500 mg/ml, 450 mg/ml to 550 mg/ml, 500 mg/ml to 600 mg/ml, 550 mg/ml to 650 mg/ml, 600 mg/ml to 700 mg/ml, 650 mg/ml to 750 mg/ml, 700 mg/ml to 800 mg/ml, 850 mg/ml to 950 mg/ml, 900 mg/ml to 1000 mg/ml or more. [0039] In some embodiments, the compositions can include glutathione in the amount of 10 mg/ml, 20 mg/ml, 30 mg/ml, 40 mg/ml, 50 mg/ml, 60 mg/ml, 70 mg/ml, 80 mg/ml, 90 mg/ml, 100 mg/ml, 200 mg/ml, 300 mg/ml, 400 mg/ml, 500 mg/ml, 600 mg/ml, 700 mg/ml, 800 mg/ml, or more. In some embodiments, the compositions can include glutathione in the amount of 15 mg/ml, 16 mg/ml, 17 mg/ml, 18 mg/ml, 19 mg/ml, 20 mg/ml, 21 mg/ml, 22 mg/ml, 23 mg/ml, 24 mg/ml, 25 mg/ml, 26 mg/ml, 27 mg/ml, 28 mg/ml, 29 mg/ml, 30 mg/ml, 31 mg/ml, 32 mg/ml, 33 mg/ml, 34 mg/ml, 35 mg/ml, 36 mg/ml, 37 mg/ml, 38 mg/ml, 39 mg/ml, or 40 mg/ml.
[0040] In some embodiments, the compositions can include CoQ10 in the amount of from about 0.1 mg to 1 mg, about 0.5 mg to 5 mg, 1 mg to 10 mg, 5 mg to 50 mg, 10 mg to 100 mg, 50 mg to 150 mg, 100 mg to 200 mg, 150 mg to 250 mg, 200 mg to 300 mg, 250 mg to 350 mg, 300 mg to 400 mg, 350 mg to 450 mg, 400 mg to 500 mg, 450 mg to 550 mg, 500 mg to 600 mg, 550 mg to 650 mg, 600 mg to 700 mg, 650 mg to 750 mg, 700 mg to 800 mg, 850 mg to 950 mg, 900 mg to 1000 mg or more.
[0041 ] In some embodiments, the compositions can include CoQ10 in the amount of 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, or more. In some embodiments, the compositions can include CoQ10 in the amount of 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg, or 300 mg.
[0042] In some embodiments, the compositions can include CoQ10 in the amount of from about 0.1 mg/ml to 1 mg/ml, about 0.5 mg/ml to 5 mg/ml, 1 mg/ml to 10 mg/ml, 5 mg/ml to 50 mg/ml, 10 mg/ml to 100 mg/ml, 50 mg/ml to 150 mg/ml, 100 mg/ml to 200 mg/ml, 150 mg/ml to 250 mg/ml, 200 mg/ml to 300 mg/ml, 250 mg/ml to 350 mg/ml, 300 mg/ml to 400 mg/ml, 350 mg/ml to 450 mg/ml, 400 mg/ml to 500 mg/ml, 450 mg/ml to 550 mg/ml, 500 mg/ml to 600 mg/ml, 550 mg/ml to 650 mg/ml, 600 mg/ml to 700 mg/ml, 650 mg/ml to 750 mg/ml, 700 mg/ml to 800 mg/ml, 850 mg/ml to 950 mg/ml, 900 mg/ml to 1000 mg/ml or more. [0043] In some embodiments, the compositions can include CoQ10 in the amount of 10 mg/ml, 20 mg/ml, 30 mg/ml, 40 mg/ml, 50 mg/ml, 60 mg/ml, 70 mg/ml, 80 mg/ml, 90 mg/ml, 100 mg/ml, 200 mg/ml, 300 mg/ml, 400 mg/ml, 500 mg/ml, 600 mg/ml, 700 mg/ml, 800 mg/ml, or more. In some embodiments, the compositions can include CoQ10 in the amount of 15 mg/ml, 16 mg/ml, 17 mg/ml, 18 mg/ml, 19 mg/ml, 20 mg/ml, 21 mg/ml, 22 mg/ml, 23 mg/ml, 24 mg/ml, 25 mg/ml, 26 mg/ml, 27 mg/ml, 28 mg/ml, 29 mg/ml, 30 mg/ml, 31 mg/ml, 32 mg/ml, 33 mg/ml, 34 mg/ml, 35 mg/ml, 36 mg/ml, 37 mg/ml, 38 mg/ml, 39 mg/ml, or 40 mg/ml. [0044] In some embodiments, the compositions can include pyrroloquinoline quinone in the amount of from about 0.1 mg to 1 mg, about 0.5 mg to 5 mg, 1 mg to 10 mg, 5 mg to 50 mg, 10 mg to 100 mg, 50 mg to 150 mg, 100 mg to 200 mg, 150 mg to 250 mg, 200 mg to 300 mg, 250 mg to 350 mg, 300 mg to 400 mg, 350 mg to 450 mg, 400 mg to 500 mg, 450 mg to 550 mg, 500 mg to 600 mg, 550 mg to 650 mg, 600 mg to 700 mg, 650 mg to 750 mg, 700 mg to 800 mg, 850 mg to 950 mg, 900 mg to 1000 mg or more.
[0045] In some embodiments, the compositions can include pyrroloquinoline quinone in the amount of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, or more. In some embodiments, the compositions can include CoQ10 in the amount of 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, or 30 mg.
[0046] In some embodiments, the compositions can include pyrroloquinoline quinone in the amount of from about 0.1 mg/ml to 1 mg/ml, about 0.5 mg/ml to 5 mg/ml, 1 mg/ml to 10 mg/ml, 5 mg/ml to 50 mg/ml, 10 mg/ml to 100 mg/ml, 50 mg/ml to 150 mg/ml, 100 mg/ml to 200 mg/ml, 150 mg/ml to 250 mg/ml, 200 mg/ml to 300 mg/ml, 250 mg/ml to 350 mg/ml, 300 mg/ml to 400 mg/ml, 350 mg/ml to 450 mg/ml, 400 mg/ml to 500 mg/ml, 450 mg/ml to 550 mg/ml, 500 mg/ml to 600 mg/ml, 550 mg/ml to 650 mg/ml, 600 mg/ml to 700 mg/ml, 650 mg/ml to 750 mg/ml, 700 mg/ml to 800 mg/ml, 850 mg/ml to 950 mg/ml, 900 mg/ml to 1000 mg/ml or more.
[0047] In some embodiments, the compositions can include pyrroloquinoline quinone in the amount of 1 mg/ml, 2 mg/ml, 3 mg/ml, 4 mg/ml, 5 mg/ml, 6 mg/ml, 7 mg/ml, 8 mg/ml, 9 mg/ml, 10 mg/ml, 20 mg/ml, 30 mg/ml, 40 mg/ml, 50 mg/ml, 60 mg/ml, 70 mg/ml, 80 mg/ml, or more. In some embodiments, the compositions can include pyrroloquinoline quinone in the amount of 1.5 mg/ml, 1.6 mg/ml, 1.7 mg/ml, 1.8 mg/ml, 1.9 mg/ml, 2.0 mg/ml, 2.1 mg/ml, 2.2 mg/ml, 2.3 mg/ml, 2.4 mg/ml, 2.5 mg/ml, 2.6 mg/ml, 2.7 mg/ml, 2.8 mg/ml, 2.9 mg/ml, 3.0 mg/ml, 3.1 mg/ml, 3.2 mg/ml, 3.3 mg/ml, 3.4 mg/ml, 3.5 mg/ml, 3.6 mg/ml, 3.7 mg/ml, 3.8 mg/ml, 3.9 mg/ml, or 4.0 mg/ml.
[0048] In some embodiments, the compositions can include iron binding glycoprotein in the amount of from about 0.1 mg to 1 mg, about 0.5 mg to 5 mg, 1 mg to 10 mg, 5 mg to 50 mg, 10 mg to 100 mg, 50 mg to 150 mg, 100 mg to 200 mg, 150 mg to 250 mg, 200 mg to 300 mg, 250 mg to 350 mg, 300 mg to 400 mg, 350 mg to 450 mg, 400 mg to 500 mg, 450 mg to 550 mg, 500 mg to 600 mg, 550 mg to 650 mg, 600 mg to 700 mg, 650 mg to 750 mg, 700 mg to 800 mg, 850 mg to 950 mg, 900 mg to 1000 mg or more.
[0049] In some embodiments, the compositions can include iron binding glycoprotein in the amount of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, or more. In some embodiments, the compositions can include iron binding glycoprotein in the amount of 65 mg, 66 mg, 67 mg, 68 mg, 69 mg, 70 mg, 71 mg, 72 mg, 73 mg, 74 mg, 75 mg, 76 mg, 77 mg, 78 mg, 79 mg, or 80 mg.
[0050] In some embodiments, the compositions can include iron binding glycoprotein in the amount of from about 0.1 mg/ml to 1 mg/ml, about 0.5 mg/ml to 5 mg/ml, 1 mg/ml to 10 mg/ml, 5 mg/ml to 50 mg/ml, 10 mg/ml to 100 mg/ml, 50 mg/ml to 150 mg/ml, 100 mg/ml to 200 mg/ml, 150 mg/ml to 250 mg/ml, 200 mg/ml to 300 mg/ml, 250 mg/ml to 350 mg/ml, 300 mg/ml to 400 mg/ml, 350 mg/ml to 450 mg/ml, 400 mg/ml to 500 mg/ml, 450 mg/ml to 550 mg/ml, 500 mg/ml to 600 mg/ml, 550 mg/ml to 650 mg/ml, 600 mg/ml to 700 mg/ml, 650 mg/ml to 750 mg/ml, 700 mg/ml to 800 mg/ml, 850 mg/ml to 950 mg/ml, 900 mg/ml to 1000 mg/ml or more.
[0051 ] In some embodiments, the compositions can include iron binding glycoprotein in the amount of 1 mg/ml, 2 mg/ml, 3 mg/ml, 4 mg/ml, 5 mg/ml, 6 mg/ml, 7 mg/ml, 8 mg/ml, 9 mg/ml, 10 mg/ml, 20 mg/ml, 30 mg/ml, 40 mg/ml, 50 mg/ml, 60 mg/ml, 70 mg/ml, 80 mg/ml, or more. In some embodiments, the compositions can include pyrroloquinoline quinone in the amount of 5 mg/ml, 5.5 mg/ml, 6 mg/ml, 6.5 mg/ml, 7 mg/ml, 7.5 mg/ml, 8 mg/ml, 8.5
mg/ml, 9 mg/ml, 9.5 mg/ml, 10 mg/ml, 10.5 mg/ml, 11 mg/ml, 11.5 mg/ml, 12 mg/ml, 12.5 mg/ml, 13 mg/ml, 13.5 mg/ml, 14 mg/ml, 14.5 mg/ml, 15 mg/ml, 15.5 mg/ml, 16 mg/ml, 16.5 mg/ml, 17 mg/ml, 17.5 mg/ml, 18 mg/ml, 18.5 mg/ml, 19 mg/ml, 19.5 mg/ml or more.
[0052] As a non-limiting example, the compositions of the disclosure can include the following components: glutathione (about 100, 200, 220, 300, or 400 mg); CoQ10 (about 100, 200, 220, 300, or400 mg), pyrroloquinoline quinone (about 5, 10, 15, 20, 30, or40 mg) and/or iron binding glycoprotein e.g., lactoferrin (about 40, 50, 60, 70, 80, 90, or 100 mg). In some embodiments, the compositions can include glutathione (about 15, 20, 22, 25, 30, or 40 mg/ml); CoQ10 (about 15, 20, 22, 25, 30 or 40 mg/ml), pyrroloquinoline quinone (about 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, or 3.5 mg/ml) and/or iron binding glycoprotein e.g., lactoferrin (about 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg/ml).
[0053] As a non-limiting example, the compositions of the disclosure can include the following components: glutathione (about 220 mg); CoQ10 (about 220 mg), pyrroloquinoline quinone (about 20 mg) and/or iron binding glycoprotein e.g., lactoferrin (about 70 mg). In some embodiments, the compositions can include glutathione (about 22 mg/ml); CoQ10 (about 22 mg/ml), pyrroloquinoline quinone (about 2 mg/ml) and/or iron binding glycoprotein e.g., lactoferrin (about 7 mg/ml).
Formulations
[0054] In some embodiments, the compositions can be administered to humans, human patients or subjects. Although the descriptions of formulations provided herein are principally directed to formulations which are suitable for administration to humans, it will be understood by the skilled artisan that such therapeutic agents are generally suitable for administration to any other animal, e.g., to non-human animals, e.g., non-human mammals. Modifications of formulations can be used such that they are suitable for administration to humans.
[0055] Formulations of compositions of glutathione, CoQ10, pyrroloquinoline quinone and/or iron binding glycoprotein described herein can be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include the step of bringing the glutathione, CoQ10, pyrroloquinoline quinone and/or iron binding glycoprotein into association with an excipient and/or one or more other accessory ingredients, and then, if necessary and/or desirable, dividing, shaping and/or packaging the product into a desired single- or multi-dose unit. As a non-limiting example, the single-dose unit can be 10 ml.
[0056] A formulation in accordance with the disclosure can be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses. As used herein, a “unit dose” is discrete amount of the formulation comprising a predetermined amount of the compositions of glutathione, CoQ10, pyrroloquinoline quinone and/or iron binding glycoprotein. The amount of glutathione, CoQ10, pyrroloquinoline quinone and/or iron binding glycoprotein is generally equal to the dosage which would be administered to a subject and/or a convenient fraction of such a dosage such as, for example, one-half or one- third of such a dosage.
[0057] Relative amounts of one or more of glutathione, CoQ10, pyrroloquinoline quinone and/or iron binding glycoprotein, the excipients, and/or any additional ingredients in a formulation in accordance with the disclosure can vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the formulation is to be administered. By way of example, the formulation can include between 0.1 % and 100%, e.g., between .5 and 50%, between 1-30%, between 5-80%, or, in some embodiments, at least 20%, at least 40%, at least 60%, or at least 80% (w/w) of one or more of glutathione, CoQ10, pyrroloquinoline quinone and/or iron binding glycoprotein.
[0058] The compositions of glutathione, CoQ10, pyrroloquinoline quinone and/or iron binding glycoprotein of the present disclosure can be formulated using one or more excipients to: (1) increase stability; (2) permit the sustained or delayed release; (3) alter the biodistribution; (4) alter the release profile of glutathione, CoQ10, pyrroloquinoline quinone and/or iron binding glycoprotein in vivo.
[0059] In one embodiment, the compositions are formulated to safely pass through the gastric environment.
Excipients
[0060] Formulations can additionally comprise an excipient, which, as used herein, includes any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, and the like, as suited to the particular dosage form desired. Remington’s The Science and Practice of Pharmacy, 21st Edition, A. R. Gennaro (Lippincott, Williams & Wilkins, Baltimore, MD, 2006; incorporated herein by reference in its entirety) discloses various excipients used in preparing formulations and known techniques for the preparation thereof. Except insofar as any conventional excipient medium is incompatible
with a substance or its derivatives, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the formulation, its use is contemplated to be within the scope of this disclosure.
[0061 ] In some embodiments, an excipient is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% pure. In some embodiments, an excipient is approved for use in humans and for veterinary use. In some embodiments, an excipient is approved by United States Food and Drug Administration. In some embodiments, an excipient is pharmaceutical grade. In some embodiments, an excipient meets the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia, and/or the International Pharmacopoeia.
[0062] Formulations can include excipients, such as without limitation, binders, coating, disintegrants, fillers, diluents, flavors, colors, lubricants, glidants, preservatives, sorbents, sweeteners, conjugated linoleic acid (CLA), gelatin, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, oils, beeswax, purified water, glycerol, any type of oil, including, without limitation, fish oil or soybean oil, or the like.
[0063] Formulations can comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as, e.g., polyethylene glycols.
[0064] Exemplary diluents include, but are not limited to, calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, etc., and/or combinations thereof.
[0065] Exemplary granulating and/or dispersing agents include, but are not limited to, potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cationexchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked polyvinylpyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble
starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (VEEGUM®), sodium lauryl sulfate, quaternary ammonium compounds, etc., and/or combinations thereof.
[0066] Exemplary surface active agents and/or emulsifiers include, but are not limited to, natural emulsifiers (e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g., bentonite [aluminum silicate] and VEEGUM® [magnesium aluminum silicate]), long chain amino acid derivatives, high molecular weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g., carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polymer), carrageenan, cellulosic derivatives (e.g., carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose), sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monolaurate [TWEEN®20], polyoxyethylene sorbitan [TWEENn®60], polyoxyethylene sorbitan monooleate [TWEEN®80], sorbitan monopalmitate [SPAN®40], sorbitan monostearate [SPAN®60], sorbitan tristearate [SPAN®65], glyceryl monooleate, sorbitan monooleate [SPAN®80]), polyoxyethylene esters (e.g., polyoxyethylene monostearate [ YRJ®45], polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and SOLUTOL®), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g., CREMOPHOR®), polyoxyethylene ethers, (e.g., polyoxyethylene lauryl ether [BRIJ®30]), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, PLUORINC®F 68, POLOXAMER®188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, etc. and/or combinations thereof.
[0067] Exemplary binding agents include, but are not limited to, starch (e.g., cornstarch and starch paste); gelatin; sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol,); natural and synthetic gums (e.g., acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, polyvinylpyrrolidone), magnesium aluminum silicate (Veegum®), and larch arabogalactan); alginates;
polyethylene oxide; polyethylene glycol; inorganic calcium salts; silicic acid; polymethacrylates; waxes; water; alcohol; etc.; and combinations thereof.
[0068] Exemplary preservatives can include, but are not limited to, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and/or other preservatives. Preservatives can be used to prevent spoilage from bacteria, molds, fungi, or yeast (antimicrobials); slow or prevent changes in color, flavor, or texture and delay rancidity (antioxidants); and/or maintain freshness. Exemplary antimicrobial preservatives include, but are not limited to, benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and/or thimerosal. Exemplary antifungal preservatives include, but are not limited to, butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and/or sorbic acid. Exemplary alcohol preservatives include, but are not limited to, ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and/or phenylethyl alcohol. Exemplary acidic preservatives include, but are not limited to, vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and/or phytic acid. Other preservatives include, but are not limited to, tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluened (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, GLYDANT PLUS®, PHENONIP®, methylparaben, GERMALL®115, GERMABEN®II, NEOLONE™ , KATHON™ , and/or EUXYL®.
[0069] Exemplary buffering agents include, but are not limited to, citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium
phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer’s solution, ethyl alcohol, etc., and/or combinations thereof.
[0070] Exemplary oils include, but are not limited to, almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, chamomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savoury, sea buckthorn, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut, and wheat germ oils. Exemplary oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and/or combinations thereof.
[0071 ] In some embodiments, the formulations can include almond butter, acorn butter, cashew butter, hazelnut butter, macadamia nut butter, peanut butter, pecan butter, pistachio butter, walnut butter, pumpkin seed butter, sesame seed butter (tahini), soybean butter, and/or sunflower seed butter. As a non-limiting example, the formulation can include about 5- 25% almond butter.
[0072] In some embodiments, the formulations can include sweeteners. These can be used to add sweetness with or without the extra calories. Nonlimiting examples of sweeteners include sucrose (sugar), glucose, fructose, sorbitol, mannitol, corn syrup, high fructose com syrup, saccharin, aspartame, sucralose, acesulfame potassium (acesulfame-K), and/or neotame.
[0073] In some embodiments, the formulations can include color additives. These can be used to offset color loss due to exposure to light, air, temperature extremes, moisture and storage conditions; correct natural variations in color; enhance colors that occur naturally; and/or to provide color to colorless foods. Nonlimiting examples of color additives include FD&C Blue Nos. 1 and 2, FD&C Green No. 3, FD&C Red Nos. 3 and 40, FD&C Yellow Nos.
5 and 6, Orange B, Citrus Red No. 2, annatto extract, beta-carotene, grape skin extract, cochineal extract or carmine, paprika oleoresin, caramel color, fruit and vegetable juices, and/or saffron. In some embodiments, the formulations can be dark orange to brown in color. [0074] In some embodiments, the formulations can include flavors and spices. These can be used to add specific flavors (natural and synthetic). Nonlimiting examples include natural flavoring, artificial flavor, and spices e.g., orange, cinnamon, vanillin, vanilla extract, mango extract, cinnamon, citrus, coconut, ginger, viridiflorol, almond, menthol (including menthol without mint), grape skin extract, and/or grape seed extract.
[0075] In some embodiments, the formulations can include flavor enhancers. These can be used to enhance flavors already present in foods (without providing their own separate flavor). Nonlimiting examples of flavor enhancers include monosodium glutamate (MSG), hydrolyzed soy protein, autolyzed yeast extract, disodium guanylate or inosinate.
[0076] In some embodiments, the formulations can include nutrients. These can be used to replace vitamins and minerals lost in processing (enrichment), add nutrients that can be lacking in the diet (fortification). Nonlimiting examples of nutrients include thiamine hydrochloride, riboflavin (Vitamin B2), niacin, niacinamide, folate or folic acid, beta carotene, potassium iodide, iron or ferrous sulfate, alpha tocopherols, ascorbic acid, Vitamin D, amino acids (L-tryptophan, L-lysine, L-leucine, L-methionine).
[0077] In some embodiments, the formulations can include stabilizers and thickeners, binders, and/or texturizers. These can be used to produce uniform texture, improve "mouthfeel." Non-limiting examples include gelatin, pectin, guar gum, carrageenan, xanthan gum, whey.
[0078] In some embodiments, the formulations can include pH control agents and acidulants. These can be used to control acidity and alkalinity, prevent spoilage. Nonlimiting examples include lactic acid, citric acid, ammonium hydroxide, or sodium carbonate.
[0079] In some embodiments, the formulations can include humectants. These can be used to retain moisture. Nonlimiting examples of humectants include glycerin, or sorbitol.
[0080] In some embodiments, the formulations of the disclosure can include gelling ingredients such as, but not limited to gelatin, alginate, carageenan, gum, pectin, konjac, agar, food acid, rennet, starch, starch derivatives, and/or combinations thereof.
[0081 ] In some embodiments, the formulations described herein can include one or more of natural almond butter, glycerin, medium chain triglycerides (MCT oil), oleic acid (from olive
oil), phosphatidylcholine, natural clove oil, orange oil, cinnamon oil, vitamin E (as D alpha tocopherol), milk and/or vanilla bean extract.
[0082] Depending on the intended mode of administration, the formulation used can be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions or the like, preferably in forms of unit dosage suitable for individual administration of precise dosages.
[0083] The formulation can be in the form of a gel, a tablet, a capsule, a liquid, an aerosol, a powder, an effervescent tablet or powder, a syrup, an emulsion, a suspension, a solution, or any other form for providing the formulation to a subject. In particular embodiments, the formulation can be in a form for oral administration, buccal administration, sublingual administration, or any other route of administration as known in the art.
[0084] In some embodiments, the nitrogen gas is utilized to remove oxygen from the formulation prior to packaging.
Liposomes
[0085] In some embodiments, the formulations of the disclosure are prepared as liposomes. A liposome is a microscopic structure made of one or more layers of phospholipid materials resembling the phospholipid that make up cell membranes. The outer portion of the liposome can be fat soluble, while the inner portion of the liposome can be water-soluble. [0086] Liposomes can include lipids having two hydrocarbon chains, typically acyl chains, and a head group, either polar or nonpolar. The hydrocarbon chains can be saturated or have varying degrees of unsaturation. The two hydrocarbon chains of the lipid can be symmetrical or asymmetrical. The acyl chains of the lipids can be saturated or unsaturated. Non limiting examples of saturated acyl groups include, trianoic, tetranoic, pentanoic, hexanoic, heptanoic, octanoic, nonanoic, decanoic, undecanoic, dodecanoic, tridecanoic, tetradecanoic, pentadecanoic, hexadecanoic, 3,7,11 ,15-tetramethylhexadecanoic, heptadecanoic, octadecanoic, nonadecanoic, eicosanoic, heneicosanoic, docosanoic, trocosanoic and tetracosanoic. Non-limiting examples of unsaturated acyl groups include 9- cis-tetradecanoic, 9-cis-hexadecanoic, 9-cis-octadecanoic, 9-trans-octadecanoic, 9-cis-12- cis-octadecadienoic, 9-cis-12-cis-15-cis-octadecatrienoic, 11-cis-eicosenoic and 5-cis-8-cis- 11 -cis-14-cis-eicosatetraenoic.
[0087] Liposomes can include lipids, such as, but not limited to, sphingolipids, ether lipids, sterols, phospholipids, particularly the phosphoglycerides, and the glycolipids, such as the cerebrosides and/or gangliosides.
[0088] In some embodiments, the liposomes can contain phosphoglycerides. Phosphoglycerides include phospholipids such as phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid, phosphatidylinositol, phosphatidylserine phosphatidylglycerol and diphosphatidylglycerol (cardiolipin), where the two hydrocarbon chains are typically between about 14-22 carbon atoms in length and have varying degrees of unsaturation.
[0089] In some embodiments, the liposomes can contain phosphatidylcholines. Exemplary phosphatidylcholines include dilauroyl phophatidylcholine, dimyristoylphophatidylcholine, dipalmitoylphophatidylcholine, distearoylphophatidyl-choline, diarachidoylphophatidylcholine, dioleoylphophatidylcholine, dilinoleoyl-phophatidylcholine, dierucoylphophatidylcholine, palmitoyl-oleoyl-phophatidylcholine, egg phosphatidylcholine, myristoyl-palmitoylphosphatidylcholine, palmitoyl-myristoyl-phosphatidylcholine, myristoylstearoylphosphatidylcholine, palmitoyl-stearoyl-phosphatidylcholine, stearoylpalmitoylphosphatidylcholine, stearoyl-oleoyl-phosphatidylcholine, stearoyl- linoleoylphosphatidylcholine and palmitoyl-linoleoyl-phosphatidylcholine. Asymmetric phosphatidylcholines are referred to as 1-acyl, 2-acyl-sn-glycero-3-phosphocholines, wherein the acyl groups are different from each other. Symmetric phosphatidylcholines are referred to as 1,2-diacyl-sn-glycero-3-phosphocholines. As used herein, the abbreviation “PC” refers to phosphatidylcholine. The phosphatidylcholine 1 ,2-dimyristoyl-sn-glycero-3- phosphocholine is abbreviated herein as “DMPC.” The phosphatidylcholine 1 ,2-dioleoyl-sn- glycero-3-phosphocholine is abbreviated herein as “DOPC.” The phosphatidylcholine 1 ,2- dipalmitoyl-sn-glycero-3-phosphocholine is abbreviated herein as “DPPC.” Liposomes can include “caged” phospholipids. Caged phospholipids are amino phospholipids that when present in a liposome, render the liposome pH-sensitive so that once endocytosed into target cells the caging groups are cleaved. This cleavage results in destabilization of the liposome, causing the uncaged lipids of the liposome to become fusogenic and to thereby release of the active agent (e.g., compositions described herein) carried by the liposome into the cell. [0090] In some embodiments, the liposomes can contain phosphatidylethanolamines. Exemplary phosphatidylethanolamines include dimyristoyl-phosphatidylethanolamine,
dipalmitoyl-phosphatidylethanolamine, distearoyl-phosphatidylethanolamine, dioleoylphosphatidylethanolamine and egg phosphatidylethanolamine.
[0091 ] In some embodiments, the liposomes can contain phosphatidic acids. Exemplary phosphatidic acids include dimyristoyl phosphatidic acid, dipalmitoyl phosphatidic acid and dioleoyl phosphatidic acid.
[0092] In some embodiments, the liposomes can contain phosphatidylserines. Exemplary phosphatidylserines include dimyristoyl phosphatidylserine, dipalmitoyl phosphatidylserine, dioleoylphosphatidylserine, distearoyl phosphatidylserine, palmitoyl-oleylphosphatidylserine and brain phosphatidylserine.
[0093] In some embodiments, the liposomes can contain phosphatidylglycerols. Exemplary phosphatidylglycerols include dilauryloylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, distearoylphosphatidylglycerol, dioleoyl- phosphatidylglycerol, dimyristoylphosphatidylglycerol, palmitoyl-oleoyl-phosphatidylglycerol and egg phosphatidylglycerol. The phosphatidylglycerol 1 ,2-dimyristoyl-sn-glycero-3- [phospho-rac-(1 -glycerol)] is abbreviated herein as “DMPG”. The phosphatidylglycerol 1 ,2- dipalmitoyl-sn-glycero-3-(phospho-rac-1 -glycerol) (sodium salt) is abbreviated herein as “DPPG”.
[0094] In some embodiments, the liposomes can contain sphingomyelins. Suitable sphingomyelins can include brain sphingomyelin, egg sphingomyelin, dipalmitoyl sphingomyelin, and distearoyl sphingomyelin.
[0095] Other suitable lipids for use in liposomes include glycolipids, sphingolipids, ether lipids, glycolipids such as the cerebrosides and gangliosides, and sterols, such as cholesterol or ergosterol.
[0096] The overall surface charge of the liposome can affect the tissue uptake of a liposome. In certain embodiments, anionic phospholipids such as phosphatidylserine, phosphatidylinositol, phosphatidic acid, and cardiolipin are used In some embodiments, liposome can include neutral lipids such as dioleoylphosphatidyl ethanolamine (DOPE). In some embodiments, cationic lipids can contain a lipophilic moiety, such as a sterol, an acyl or diacyl chain, and where the lipid has an overall net positive charge.
[0097] Liposomes containing formulations of the disclosure having a more rigid lipid bilayer, or a liquid crystalline bilayer, are achieved by incorporation of a relatively rigid lipid. The rigidity of the lipid bilayer correlates with the phase transition temperature of the lipids
present in the bilayer. Phase transition temperature is the temperature at which the lipid changes physical state and shifts from an ordered gel phase to a disordered liquid crystalline phase. Several factors affect the phase transition temperature of a lipid including hydrocarbon chain length and degree of unsaturation, charge and headgroup species of the lipid. Lipid having a relatively high phase transition temperature can be used to produce a more rigid bilayer. Other lipid components, such as cholesterol, are also known to contribute to membrane rigidity in lipid bilayer structures.
[0098] In some embodiments, the liposomes can be hollow microspheres of different sizes, ranging from 50nm to 1000nm, made up of one or more lipid bilayers that enclose a hydrophilic core. In an aqueous medium, hydrophobic tails attract each other, while hydrophilic heads tend to face water. The result is lipid bilayers that close to form small vesicles within which there is a varied hydrophilic environment. In some embodiments, the hydrophilic core can include glutathione (GSH), pyrroloquinoline quinone, and/or iron binding glycoprotein. In some embodiments, the CoQ10 of the composition can be associated with a hydrophobic portion of the liposomes, e.g., the hydrophobic tails of lipids making up the liposomes, a lipid bilayer of the liposomes, or a lipid membrane of the liposomes.
[0099] Liposomes can be classified according to their size and number of lipid bilayers. Liposomes can be multilamellar liposome vesicles: they have an onion-like structure in which various lipid bilayers are intercalated with hydrophilic layers; unilamellar liposomes vesicles formed by a single lipid bilayer and enclose a strongly hydrophilic nucleus or oligolamellar vesicles, made up of several lipid bilayers that enclose a markedly hydrophobic environment. [0100] In one embodiment, the liposomes, can be, multilamellar vesicles (MLV), microemulsified liposomes (MEL), or large unilamellar vesicles (LUVET).
[0101 ] In some embodiments, the liposomes can have a length or diameter of about 1 - 10 nm, 5 - 15 nm, 10 - 20 nm, 15 - 25 nm, 20 - 30 nm, 25 - 35 nm, 30 - 40 nm, 35 - 45 nm, 40 - 50 nm, 45 - 55 nm, 50 - 60 nm, 55 - 65 nm, 60 - 70 nm, 65 - 75 nm, 70 - 80 nm, 75 - 85 nm, 80 - 90 nm, 85 - 95 nm, 90 - 100 nm, 100 - 200 nm, 150 - 250 nm, 200 - 300 nm, 250 - 350 nm, 300 - 400 nm, 350 - 450 nm, 400 - 500 nm, 450 - 550 nm, 500 - 600 nm, 550 - 650 nm, 600 - 700 nm, 650 - 750 nm, 700 - 800 nm, 750 - 850 nm, 800 - 900 nm, 850 - 950 nm, 900 - 1000 nm, 1000 - 10000 nm, 10000 - 20000 nm, 20000 - 30000 nm, 30000 - 40000 nm, 40000 - 50000 nm, 50000 - 60000 nm, 60000 - 70000 nm, 70000 - 80000 nm, 80000 - 90000
nm, or 90000 - 100000 nm. As a non-limiting example, the liposome can be 20 nm in length or diameter.
[0102] Liposomes can be prepared by hydrating the lipids, followed by sizing of the particles and removing of the non encapsulated composition. Liposomes can be prepared by passive loading mechanical dispersion methods and/or active loading methods, or any other suitable method. In some embodiments, liposomes are prepared by thin-film hydration method, micro emulsification, sonication, membrane extrusion, freeze thawed method, ether injection method, ethanol injection method, reverse phase evaporation method, dehydration- rehydration, and/or calcium-induced fusion method. In some embodiments, the liposomes of the disclosure are prepared by passive loading method where the composition is encapsulated by introducing an aqueous phase of a water-soluble components of the composition and/or an organic phase of the lipid-soluble components of the composition, before or at some stage during the preparation of the liposomes.
[0103] In some embodiments, the liposomes can be prepared by the thin-film hydration procedure, where liposomes are prepared by dissolving the phospholipids in organic solvents, such as, dichloromethane, chloroform, ethanol, and/or chloroform-methanol mixture. A thin and homogeneous lipid film can be formed the solvent is evaporated under vacuum at the temperature: about 45-60 °C. Nitrogen gas can be used to completely remove the residual solvent. A solution of distilled water, phosphate buffer, phosphate saline buffer at pH 7.4 and normal saline buffer can be used in hydration step. The time for the hydration process can be about 1 hour to 2 hours at a temperature of about 60-70 °C. In order to obtain full lipid hydration, the liposomal suspension can be left overnight at about 4-6 °C.
[0104] In some embodiments, the liposomes can be prepared by injection methods. For example, the liposomes can be prepared by the ether injection method. This method uses a solution of lipids that can be dissolved in ether and/or diethyl ether/methanol mixture which is slowly injected to an aqueous solution of the composition to be capsulated. The subsequent removal of the organic solvent under reduced pressure can lead to the formation of liposomes. In some embodiments, the liposomes can be prepared by ethanol injection method wherein the ethanolic lipid solution can be rapidly injected to a vast excess of preheated distilled water or TRIS-HCI buffer. The incorporation of the composition in liposomal vesicle can depend on its hydrophilic/hydrophobic character. In some embodiments, the liposomes can be prepared by the sonication method. The sonication
method is based on size transformation and involves the subsequent sonication of multilamellar vesicles (MLVs) prepared by thin-film hydration method, using sonic energy usually under an inert atmosphere including nitrogen or argon. The sonication method enables homogenous dispersion of small vesicles using bath type or probe type sonicator with a potential for greater tissue penetration. The bath sonicators can be used for preparation of small unilamellar vesicles (SUVs). In some embodiments, MLVs can be prepared by thin-film hydration method by repeatedly passing the composition and lipids through filters of polycarbonate membranes. The liposomes can be prepared using thin-film hydration method subsequently using an extruder for ten cycles to obtain extruded liposomes with uniform diameters.
[0105] In some embodiments, the liposomes can be prepared by reverse-phase evaporation method. In this method, organic solvents such as diethyl ether/isopropyl ether or mixture of diethyl ether and chloroform (1 :1 v/v) and a mixture of chloroform methanol (2:1 v/v)2 can be used. The organic phase can be immiscible with aqueous phase thus an oil/water emulsion can be created. Phosphate buffer saline or citric-Na2HPO4 buffer can be added to aqueous phase with aim to improve the efficiency of liposome formulations. The formation of liposomes can be allowed by continued rotary evaporation of the organic solvents under vacuum.
[0106] In some embodiments, the liposomes can be prepared by the calcium-induced method. This method is based on adding of calcium to SUVs. The formation of multilamellar vesicles is as result of fusion. The addition of ethylenediaminetetraacetic acid (EDTA) to the preparations can result in the formation of large unilamellar vesicles (LUV) liposomes. The preparation of LUV liposomes can be obtained from acidic phospholipids.
[0107] In some embodiments, the liposomes can be prepared by the freezing and thawing method. The method of freezing and thawing is introduced for increasing the trapped volume of liposomal preparations. The freeze-thaw method is dependent on the ionic strength of the medium and the phospholipid concentration. It influences to a physical disruption of lamellar structure leading to formation of unilamellar vesicles. The unilamellar vesicles are rapidly frozen followed by slow thawing, while the freeze and thawing cycles are repeated.
Gels
[0108] In some embodiments, each dose of the formulation is prepared as liposomes within a gel. In some embodiments, the gel can include an oil and/or a nut butter.
[0109] Nut butter in the gel can be peanut butter, almond butter, cashew butter, pistachio butter, hazelnut butter, walnut butter, macadamia nut butter, pecan butter, Brazil nut butter, chestnut butter, pine nut butter, coconut butter, or combinations thereof.
[0110] An oil in the gel can be sunflower oil, flaxseed oil, hemp seed oil, olive oil, sesame oil, grapeseed oil, canola oil (from rapeseed plant), corn oil, peanut oil, palm oil, avocado oil, or combinations thereof.
[0111 ] In some embodiments, an oil in the gel can include at least one medium chain triglyceride (MCT) oil. As used herein, "MCT oil" means a medium chain (6 to 12 carbon) aliphatic fatty acid ester of glycerol. For example, the at least one MCT oil can be present from about 10% to about 69%, or from about 10% to about 40%, or from about 10% to about 30%, or from about 10% to about 20%, or from about 10% to about 15%, or from about 20% to about 60%, or from about 30% to about 50%, or from about 40% to about 45%, based on the total weight of the oil in the gel. For example, the MCT oil can include saturated medium chain fatty acids, for example, a plurality of saturated medium chain fatty acids. In an exemplary embodiment, the MCTs include a mixture of fatty acids having from 6 to 12 carbon atoms. The MCT oil can be derived from a plant such as a fruit or vegetable, for example, a plurality of plants. The MCT oil can contain caprylic acid, an 8-carbon saturated FA. The MCT oil can contain capric acid, a 10-carbon saturated FA. For example, the medium-chain triglycerides can contain a mixture of caprylic acid and capric acid.
[0112] In one embodiment, the formulation comprises a gel of sunflower oil, MCT oil and almond butter. The amount of sunflower oil in the gel can be 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 35 %, 40 %, 45 %, 50 %, 55 %, 60 %, 65 %, 70 %, 75 %, 80 %, 85 %, 90 %, 95 %, 100%, about 1-10%, 15-25%, 20-30%, 25-35%, 30-40%, 35-45%, 40-50%, 45-55%, 50-60%, 55-65%, 60-70%, 65-75%, 70-80%, 75-85%, 80-90%, 85-95% or more of the gel. The amount of MCT oil in the gel can be 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 35 %, 40 %, 45 %, 50 %, 55 %, 60 %, 65 %, 70 %, 75 %, 80 %, 85 %, 90 %, 95 %, 100%, about 1-10%, 15- 25%, 20-30%, 25-35%, 30-40%, 35-45%, 40-50%, 45-55%, 50-60%, 55-65%, 60-70%, 65- 75%, 70-80%, 75-85%, 80-90%, 85-95% or more of the gel. The amount of almond butter in the gel can be 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 35 %, 40 %, 45 %, 50 %, 55 %, 60 %, 65 %, 70 %, 75 %, 80 %, 85 %, 90 %, 95 %, 100%, about 1 -10%, 15-25%, 20-30%, 25-35%, 30-40%, 35-45%, 40-50%, 45-55%, 50-60%, 55-65%, 60-70%, 65-75%, 70-80%, 75-85%, 80-90%, 85-95% or more of the gel.
[0113] The formulations can also include a gelling agent such as, but not limited to agar, gellan gum, carrageenan, pectin, and/or gelatin. Thickening agents can also be added to formulations to prepare gels. Non-limiting examples of thickening agents include far celerane, locust bean gum, guar gum, gum arabic, and/or xanthan gum.
Dosing and Administration
[0114] The determination of an appropriate prescribed dosage of a composition in a formulation in order to achieve a desired biological outcome is within the skill level of an ordinary practitioner of the art.
[0115] In some embodiments, each dose of the compositions of the disclosure can include glutathione in the amount of from about 0.1 mg/ml to 1 mg/ml, about 0.5 mg/ml to 5 mg/ml, 1 mg/ml to 10 mg/ml, 5 mg/ml to 50 mg/ml, 10 mg/ml to 100 mg/ml, 50 mg/ml to 150 mg/ml, 100 mg/ml to 200 mg/ml, 150 mg/ml to 250 mg/ml, 200 mg/ml to 300 mg/ml, 250 mg/ml to 350 mg/ml, 300 mg/ml to 400 mg/ml, 350 mg/ml to 450 mg/ml, 400 mg/ml to 500 mg/ml, 450 mg/ml to 550 mg/ml, 500 mg/ml to 600 mg/ml, 550 mg/ml to 650 mg/ml, 600 mg/ml to 700 mg/ml, 650 mg/ml to 750 mg/ml, 700 mg/ml to 800 mg/ml, 850 mg/ml to 950 mg/ml, 900 mg/ml to 1000 mg/ml or more. In some embodiments, each dose of the compositions of the disclosure can include CoQ10 in the amount of from about 0.1 mg/ml to 1 mg/ml, about 0.5 mg/ml to 5 mg/ml, 1 mg/ml to 10 mg/ml, 5 mg/ml to 50 mg/ml, 10 mg/ml to 100 mg/ml, 50 mg/ml to 150 mg/ml, 100 mg/ml to 200 mg/ml, 150 mg/ml to 250 mg/ml, 200 mg/ml to 300 mg/ml, 250 mg/ml to 350 mg/ml, 300 mg/ml to 400 mg/ml, 350 mg/ml to 450 mg/ml, 400 mg/ml to 500 mg/ml, 450 mg/ml to 550 mg/ml, 500 mg/ml to 600 mg/ml, 550 mg/ml to 650 mg/ml, 600 mg/ml to 700 mg/ml, 650 mg/ml to 750 mg/ml, 700 mg/ml to 800 mg/ml, 850 mg/ml to 950 mg/ml, 900 mg/ml to 1000 mg/ml or more. In some embodiments, each dose of the compositions of the disclosure can include pyrroloquinoline quinone in the amount of the amount of from about 0.1 mg/ml to 1 mg/ml, about 0.5 mg/ml to 5 mg/ml, 1 mg/ml to 10 mg/ml, 5 mg/ml to 50 mg/ml, 10 mg/ml to 100 mg/ml, 50 mg/ml to 150 mg/ml, 100 mg/ml to 200 mg/ml, 150 mg/ml to 250 mg/ml, 200 mg/ml to 300 mg/ml, 250 mg/ml to 350 mg/ml, 300 mg/ml to 400 mg/ml, 350 mg/ml to 450 mg/ml, 400 mg/ml to 500 mg/ml, 450 mg/ml to 550 mg/ml, 500 mg/ml to 600 mg/ml, 550 mg/ml to 650 mg/ml, 600 mg/ml to 700 mg/ml, 650 mg/ml to 750 mg/ml, 700 mg/ml to 800 mg/ml, 850 mg/ml to 950 mg/ml, 900 mg/ml to 1000 mg/ml or more. . In some embodiments, each dose of the compositions of the disclosure can include iron binding glycoprotein in the amount of from about 0.1 mg/ml to 1 mg/ml, about
0.5 mg/ml to 5 mg/ml, 1 mg/ml to 10 mg/ml, 5 mg/ml to 50 mg/ml, 10 mg/ml to 100 mg/ml, 50 mg/ml to 150 mg/ml, 100 mg/ml to 200 mg/ml, 150 mg/ml to 250 mg/ml, 200 mg/ml to 300 mg/ml, 250 mg/ml to 350 mg/ml, 300 mg/ml to 400 mg/ml, 350 mg/ml to 450 mg/ml, 400 mg/ml to 500 mg/ml, 450 mg/ml to 550 mg/ml, 500 mg/ml to 600 mg/ml, 550 mg/ml to 650 mg/ml, 600 mg/ml to 700 mg/ml, 650 mg/ml to 750 mg/ml, 700 mg/ml to 800 mg/ml, 850 mg/ml to 950 mg/ml, 900 mg/ml to 1000 mg/ml or more.
[0116] In some embodiments, each dose of the formulation is prepared as gel. When prepared as a gel, each dose of the gel can have a volume of about 0.5 ml, 1 ml, 1.5 ml, 2 ml, 3 ml, 4 ml, 5 ml, 6 ml, 7 ml, 8 ml, 9 ml, 10 ml, 11 ml, 12 ml, 13 ml, 14 ml, 15 ml, 16 ml, 17 ml, 18 ml, 19 ml, 20 ml or more.
[0117] In some embodiments, each dose of the formulation can include glutathione (about 22 mg/ml); CoQ10 (about 22 mg/ml), pyrroloquinoline quinone (about 2 mg/ml) and/or iron binding glycoprotein e.g., lactoferrin (about 7 mg/ml).
[0118] In some embodiments, each dose of the formulation can include glutathione (about 275 mg); CoQ10 (about 220 mg), and/or pyrroloquinoline quinone (about 22 mg) in 15 ml of a dose of the formulation.
[0119] In some embodiments, each dose is prepared as one or more tablets or capsules. [0120] In some embodiments, the formulation can be taken once daily. In some embodiments, the formulation can be taken twice daily, three times daily, four times daily, or more than four times daily. In one example, the formulation can be taken with meals. In some embodiments, the formulation can be taken immediately following a meal. In some embodiments, the formulation is not mixed with the meal. In some embodiments, the formulation can be taken in the morning, afternoon, evening, and/or night. In one example, the formulation can be taken at the same time every day. In another example, the time the formulation is taken can vary. In one example, the daily intake can be contained in one packaging of the formulation that can be consumed once daily. In another example the daily intake can be split across more than one packaging of the formulation which can be taken together. In another example, the daily intake can be contained in two packages of the formulation and a user can administer two packages of the formulation once daily. In another example, the daily intake can be contained in three packages and a user can administer three packages once daily or administer one package of the formulation three times daily. In
another example, the daily intake can be contained in four or more packages of the formulation that can be administered one to four times daily.
[0121 ] The formulations of the disclosure can be administered for 1 day, 1 week, 1 month, 1 year or more. In some embodiments, the formulations can be administered for about 1-30 days, 1 -60 days, 1-90 days, 1-120 days, 1 -150 days or more. In some embodiments, the formulations can be administered for about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 20 days, 30 days, 40 days, 50 days, 60 days, 70 days, 80 days, 90 days, 100 days or more. In some embodiments, the formulations can be administered for 1 week, 2 weeks, 3 weeks, 4 weeks, or more. In some embodiments, the formulations can be administered for 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months or more.
[0122] Formulations of the present disclosure can be administered in the conventional manner by any route where they are active. Administration can be systemic, parenteral, topical, or oral. As a non-limiting example, administration is oral. In some embodiments, the administration can be, but is not limited to, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, oral, buccal, or ocular routes, or intravaginally , by inhalation, by depot injections, or by implants.
Methods of use
[0123] The present disclosure provides various uses and applications for the compositions of the disclosure.
[0124] In some embodiments, compositions of the disclosure can be used by individuals who do not present one or more symptoms associated with a disease, condition or a syndrome. In some embodiments, the compositions of the disclosure can be used to treat or improve symptoms associated with one or more diseases, conditions, or syndrome.
[0125] In some embodiments, the compositions of the disclosure can be used to reduce systemic fatigue, cellular inflammation, and/or reactive oxygen species.
[0126] In some embodiments, the compositions of the disclosure can be used to increase energy potential of cellular systems by increasing mitochondrial biogenesis.
[0127] In some embodiments, the compositions of the disclosure can be used to treat diseases or disorders associated with oxidative stress, such as, but not limited to, chronic fatigue syndrome, cardiovascular diseases, diabetes, cancer, chronic kidney disease, chronic obstructive pulmonary disease (COPD), neurological disease. In some
embodiments, the compositions of the disclosure can be used to treat chronic fatigue syndrome and/or major depressive disorder.
[0128] In some embodiments, the compositions of the disclosure can be used to improve lifespan or healthspan of a subject.
[0129] The subject who can benefit from the compositions of the disclosure can be of any age, such as, but not limited to about 1-10 years, 5-15 years, 10-20 years, 15-25 years, 20- 30 years, 25-35 years, 30-40 years, 35-45 years, 40-50 years, 45-55 years, 50-60 years, 55- 65 years, 60-70 years, 65-75 years, 70-80 years or more.
[0130] In some embodiments, compositions of the disclosure can prevent the occurrence of a disease. The term ‘preventing’ or ‘prevention’ refers to a reduction in risk of acquiring or developing a disease or disorder (i.e. , causing at least one of the clinical symptoms of the disease not to develop) in a subject that can be exposed to a disease-causing agent, or predisposed to the disease in advance of disease onset.
Chronic Fatigue Syndrome
[0131 ] In some embodiments, the compositions of the disclosure can be used to treat Chronic Fatigue Syndrome (CFS). CFS can be associated with decreased GSH concentration in the brain and mitochondrial dysfunction can be directly related to CFS and neuroinflammation disorders.
[0132] Chronic fatigue syndrome (CFS) is characterized by profound tiredness, regardless of bed rest. Its symptoms can worsen with physical or mental activity. CFS can happen suddenly and last for years. In some embodiments, CFS is also referred to under other names, such as, epidemic neuromyasthesia, idiopathic chronic fatigue and myalgia syndrome, chronic infectious mononucleosis, myalgic encephalomyelitis, post-viral fatigue syndrome, or fibrositis-fibromyalgia syndrome.
[0133] In some embodiments, the compositions of the disclosure can be used to improve one or more symptoms associated with CFS. In some embodiments, the compositions of the disclosure can improve one or more symptoms by 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 35 %, 40 %, 45 %, 50 %, 55 %, 60 %, 65 %, 70 %, 75 %, 80 %, 85 %, 90 %, 95 %, 100%, about 1-10%, 15-25%, 20-30%, 25-35%, 30-40%, 35-45%, 40-50%, 45-55%, 50-60%, 55-65%, 60- 70%, 65-75%, 70-80%, 75-85%, 80-90%, 85-95% or more.
[0134] The primary symptom of CFS is fatigue, which has a definite onset, and is severe, disabling and affects both physical and mental functioning, and furthermore the fatigue is present for a minimum of 6 months at which it was present for more than 50 % of the time.
[0135] Other symptoms of CFS can include sleep disturbances, which are changes in the duration of sleep and/or quality of sleep. The changes could be hypersomnia or increased sleep, or insomnia or reduced sleep, (which should further be described as either difficulty of getting off to sleep, early wakening, or subjectively disturbed or unrefreshing sleep). In some embodiments, CFS is associated with disability, which, as used herein, can refer to any restriction or lack (resulting from loss of psychological or physiological function) of ability to perform an activity in the manner or within the range considered normal for human being, i.e., things that people cannot do in the areas of occupational, social and leisure activities because of their illness. The disability associated with CFS can be distinguished from impairment of function (e.g., weak legs) and from handicap (e.g., unable to work).
[0136] Mood disturbances such as depressed mood, anhedonia, anxious mood, emotional lability and irritability, can also be associated with CFS. In some embodiments, CFS can be associated with Myalgia, which is pain or aching felt in the muscles. The myalgia can be disproportionate to exertion and can be distinguished from feelings of weakness and pain felt in other areas such as the joints.
[0137] In some embodiments, individuals with CFS can have problems with thinking and memory. Most people with CFS have trouble thinking quickly, remembering things, and paying attention to details. In some embodiments, individuals with CFS can have “brain fog” which is generally used to describe the feeling of not being able to think clearly. In some embodiments, individuals with CFS can have worsening of symptoms while standing or sitting upright. This is called orthostatic intolerance. People with CFS can be lightheaded, dizzy, weak, or faint while standing or sitting up. They can have vision changes like blurring or seeing spots.
[0138] In some embodiments, individuals with CFS can have pain (not associated with an injury), muscle pain and aches, joint pain without swelling or redness, headaches, either new or worsening, tender lymph nodes in the neck or armpits, sore throat, digestive issues, like irritable bowel syndrome, chills and night sweats, allergies and sensitivities to foods, odors, chemicals, light, or noise, muscle weakness, shortness of breath, and/or irregular heartbeat.
[0139] Worsening of CFS symptoms after physical or mental activity that would not have caused a problem before illness. This is known as post-exertional malaise (PEM). During PEM, any CFS symptoms can get worse or first appear, including difficulty thinking, problems sleeping, sore throat, headaches, feeling dizzy, or severe tiredness. It may take days, weeks, or longer to recover from a crash. Sometimes patients can be house-bound or even completely bed-bound during crashes.
[0140] In some embodiments, compositions of the disclosure can, within about 30 days, cause a reduction of fatigue, reduction in feeling of tiredness, and improve output and recovery during aerobic exercise.
[0141 ] In some embodiments, compositions of the disclosure can, within about 60 days can result in quicker recall, stronger attention span during tasks, deeper and more restorative sleep, reduction in inflammatory markers within the body in patients with CFS.
[0142] In some embodiments, the compositions of the disclosure can, within about 90 days, increase energy, alertness and activity levels, decrease creatine kinase activity and myoglobin concentration in those with exercise-induced muscle damage
Diabetes
[0143] In some embodiments, the compositions of the disclosure can be used to treat diabetes. The diabetes can be type 1 diabetes, type 2 diabetes or gestational diabetes. Reduced GSH have been associated with insulin resistance associated with type 2 diabetes. Insulin resistance can refer to the reduced or inability of the cells, tissue or organisms to take up glucose in the presence of insulin. In some embodiments, the compositions of the disclosure can reduce insulin resistance by 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 35 %, 40 %, 45 %, 50 %, 55 %, 60 %, 65 %, 70 %, 75 %, 80 %, 85 %, 90 %, 95 %, 100%, about 1- 10%, 15-25%, 20-30%, 25-35%, 30-40%, 35-45%, 40-50%, 45-55%, 50-60%, 55-65%, 60- 70%, 65-75%, 70-80%, 75-85%, 80-90%, 85-95% or more.
[0144] In some embodiments, the compositions of the disclosure can be used to improve one or more symptoms associated with diabetes including, but not limited to, fatigue, increase urination, thirst, weight loss, hunger, blurry vision, numb or tingling hands and/or feet, increase infections or delayed wound healing.
Major Depressive Disorder
[0145] In some embodiments, the compositions of the disclosure can be used to treat a subject diagnosed with major depressive disorder (MDD). MDD is a mood disorder that can
cause a persistent feeling of sadness and loss of interest. Patients with MDD have shown to have pro-inflammatory cytokines (IL-6, IL-8) as well as acute and chronic mitochondrial dysfunction. Compositions of the disclosure can be used improve one or more symptoms associated with MDD, such as, but not limited to feelings of sadness, tearfulness, emptiness or hopelessness, angry outbursts, irritability or frustration, even over small matters, loss of interest or pleasure in most or all normal activities, such as sex, hobbies or sports, sleep disturbances, including insomnia or sleeping too much, tiredness and lack of energy, so even small tasks take extra effort, reduced appetite and weight loss or increased cravings for food and weight gain, anxiety, agitation or restlessness, slowed thinking, speaking or body movements, feelings of worthlessness or guilt, fixating on past failures or self-blame, trouble thinking, concentrating, making decisions and remembering things, frequent or recurrent thoughts of death, suicidal thoughts, suicide attempts or suicide, unexplained physical problems, such as back pain or headaches.
[0146] In some embodiments, the compositions of the disclosure can improve one or more symptoms of MDD symptoms by about 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 35 %, 40 %, 45 %, 50 %, 55 %, 60 %, 65 %, 70 %, 75 %, 80 %, 85 %, 90 %, 95 %, 100%, about 1- 10%, 15-25%, 20-30%, 25-35%, 30-40%, 35-45%, 40-50%, 45-55%, 50-60%, 55-65%, 60- 70%, 65-75%, 70-80%, 75-85%, 80-90%, 85-95% or more.
Improving healthspan and/or lifespan
[0147] In some embodiments, the compositions of the disclosure provide for increasing or improving healthspan of a subject.
[0148] As used herein, “healthspan” can be defined as the period of life spent free of age- related diseases/conditions. The healthspan of a given subject can therefore refer to the period during which the subject does not have an age-related disease/condition (e.g., an age-related disease described herein). A subject can be considered to not to have a given disease/condition until they are diagnosed with a relevant disease condition.
[0149] A subject having an improved/increased/extended healthspan can remain free of an age-related disease/condition for a longer period as compared to a reference subject. In the context of the present disclosure, a subject administered with the compositions of the disclosure can have an increased healthspan as compared to an equivalent, untreated subject. The increase in healthspan can be by about 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 35 %, 40 %, 45 %, 50 %, 55 %, 60 %, 65 %, 70 %, 75 %, 80 %, 85 %, 90 %, 95 %, 100%, about
1-10%, 15-25%, 20-30%, 25-35%, 30-40%, 35-45%, 40-50%, 45-55%, 50-60%, 55-65%, 60- 70%, 65-75%, 70-80%, 75-85%, 80-90%, 85-95% or more.
[0150] Alternatively, “healthspan” can also refer to the period of life during which a subject does not exhibit significant age-related deterioration in the function of a tissue, organ or organ system of the subject. The deterioration in function can arise as a consequence of an age- related disease/condition. A subject displaying deterioration in a function of a given tissue/organ/organ system can display a level of the relevant function which is less than 1 times, e.g. one of <0.99 times, <0.95 times, <0.9 times, <0.85 times, <0.8 times, <0.75 times, <0.7 times, <0.65 times, <0.6 times, <0.55 times, <0.5 times, <0.45 times, <0.4 times, <0.35 times, <0.3 times, <0.25 times, <0.2 times, <0.15 times or <0.1 times the level observed in comparable subjects not experiencing deterioration in the relevant function.
[0151 ] In some embodiments, the compositions can also be used to extend lifespan. As used herein, lifespan can be defined as the length of time for which a person lives. The compositions of the disclosure can increase lifespan by about 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years, 15 years, 20 years, 25 years, 30 years, 35 years, 40 years, 45 years, 50 years, about 1 -2 months, 2-3 months, 3-4 months, 4-5 months, 5-6 months, 6-7 months, 7-8 months, 8-9 months, 9-10 months, 10-11 months, 1 -2 years, 2-3 years, 3-4 years, 4-5 years, 5-6 years, 6-7 years, 7-8 years, 8-9 years, 9-10 years, 10-20 years, 15-25 years, 20-30 years, 25-35 years, 30-40 years, 35-45 years, 40-50 years or more.
[0152] The compositions and methods are more particularly described below, and the Examples set forth herein are intended as illustrative only, as numerous modifications and variations therein will be apparent to those skilled in the art. The terms used in the specification generally have their ordinary meanings in the art, within the context of the compositions and methods described herein, and in the specific context where each term is used. Some terms have been more specifically defined herein to provide additional guidance to the practitioner regarding the description of the compositions and methods.
[0153] As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items. As used in the description herein and throughout the claims that follow, the meaning of “a”, “an”, and “the” includes plural reference as well as the singular reference unless the context clearly dictates otherwise. The term “about” in association with
a numerical value means that the value varies up or down by 5%. For example, for a value of about 100, means 95 to 105 (or any value between 95 and 105).
[0154] All patents, patent applications, and other scientific or technical writings referred to anywhere herein are incorporated by reference herein in their entirety. The embodiments illustratively described herein suitably can be practiced in the absence of any element or elements, limitation or limitations that are specifically or not specifically disclosed herein. Thus, for example, in each instance herein any of the terms "comprising," "consisting essentially of," and "consisting of" can be replaced with either of the other two terms, while retaining their ordinary meanings. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the claims. Thus, it should be understood that although the present methods and compositions have been specifically disclosed by embodiments and optional features, modifications and variations of the concepts herein disclosed can be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of the compositions and methods as defined by the description and the appended claims.
[0155] Any single term, single element, single phrase, group of terms, group of phrases, or group of elements described herein can each be specifically excluded from the claims.
[0156] Whenever a range is given in the specification, for example, a temperature range, a time range, a composition, or concentration range, all intermediate ranges and subranges, as well as all individual values included in the ranges given are intended to be included in the disclosure. It will be understood that any subranges or individual values in a range or subrange that are included in the description herein can be excluded from the aspects herein. It will be understood that any elements or steps that are included in the description herein can be excluded from the claimed compositions or methods
[0157] In addition, where features or aspects of the compositions and methods are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the compositions and methods are also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.
[0158] The following are provided for exemplification purposes only and are not intended to limit the scope of the embodiments described in broad terms above.
EXAMPLES
Example 1: In vivo studies in Caenorhabditis elegans
C. elegans (worm) maintenance and media
[0159] To prevent chemical modification or metabolism of the test article by the food bacteria, animals are fed on a lawn of inactivated E. coli, strain OP50. Cultures of OP50 are inactivated by exposure to 0.25% paraformaldehyde for 1 hour followed by 5 washes in M9. Bacteria are dispersed by passing through a 5pM filter during the wash steps. The quantity and distribution of food bacteria are calibrated to ensure adequate access to food for the duration of assay while maintaining visibility of the animals.
Reactive oxygen species (ROS) assay
[0160] A large population of wild-type C. elegans are synchronized and grown to the L4 juvenile stage. Liquid culture medium is prepared as follows: S medium, 50 uM 5- Fluorodeoxyuridine (FUdR), 200 pg/ml Streptomycin, and filtered OP50. The L4 animals are resuspended in liquid culture at about 2 animals/pl. 90pl of the animals in the liquid culture media are added to each well. Compositions of the disclosure are extracted into ethanol, water and/or DMSO and 10 pl are added to each well. Micro plates are sealed and incubated at 20°C overnight on shaker. The next day, activity is measured on the WMicrotracker (PhylumTech) for 2 hours and a basal measurement is obtained. 11 pl of Paraquat (1 OOmM) is pipetted to each well for a final concentration of 10mM. The plate is resealed and activity is recorded on the WMicrotracker for 48 hours. The activity is grouped in blocks of 40 minutes and percent activity is calculated by normalizing to the basal activity measurements.
[0161 ] The ROS assay is expected to show that pre-treatment with the compositions of the disclosure can provide improved protection against reactive oxygen species (ROS) than the positive control, paraquat.
Lifespan assay
[0162] The lifespan assay is initiated by expanding all groups (group treated with compositions of the disclosure and control group) to more than 1000 animals, then synchronizing by bleaching and allowing larval animals to hatch and arrest. To eliminate the effect of bacterial metabolism and growth on lifespan, synchronized animals are only exposed to dead food bacteria. To suppress progeny, animals are transferred to media
containing 5-Fluorodeoxyuridine (FUdR) within 54-60 hours post-plating. Animals are inspected 24 and 48 hours after this transfer to confirm infertility. Finally, the animals are inspected for general health and morphology before transferring to scanner plates. The scanner plates are incubated for an additional 2 days and inspected again before loading onto scanners.
[0163] To understand the physiological impact of either genetic variation or pharmacological treatment on aging, quantitative models are used. The analysis of lifespan data is grounded in the study of two mathematical functions: the survival curve and the hazard function. The survival curve describes the fraction of a tested population that remains alive over time. The hazard function is related to the survival curve and provides an intuitive measure of the risk of death. This function describes the probability that a typical individual who is currently alive will soon die, providing a clear visualization of the way a treatment can change patterns in mortality. To obtain high-resolution lifespan data and eliminate confounding factors such as worm handling and operator bias, lifespan data is collected using an Automated Lifespan Machine (ALM) which is adapted from Stroustrup, N. et al., Nat Methods 10, 665-670 (2013) (the contents of which are herein incorporated by reference in its entirety). Three biological replicates are derived from synchronizing three independently maintained lines of N2 animals. Images of the animals are then collected for the next 35 days with no interruption or manipulations.
[0164] The lifespan of the animals treated with the compositions of the disclosure is expected to increase significantly compared to untreated controls.
Survival Analysis
[0165] Time of death calls exported from the ALM software is analyzed and plotted using the Lifelines software package developed by Cam Davidson-Pilon et al., CamDavidsonPilon/lifelines: vO.25.9 (https://doi.org/10.5281/zenodo.4505728; the contents of which are herein incorporated by reference in its entirety). Additional analysis is performed using the OASIS2 analysis software. A standard Mantel-Cox log-rank test is used to compare the curves globally over the course of the lifespan assigning equal weight to each timepoint, whereas the Wilcoxon-Breslow-Gehan weights each death by the number of subjects at risk, assigning greater weight to earlier deaths. Each of these tests is expected to show a significant increase in survival upon treatment with the compositions of the disclosure compared to the control.
[0166] The survival rate is expected to increase significantly in animals treated with the compositions of the disclosure compared to untreated controls.
Movement and healthspan analysis
[0167] Worm movement is tracked from the images acquired by the ALM during the lifespan assay. Worm size and movement features are extracted and analyzed using custom software. Worm Activity serves as a proxy for animal health. Changes in spatial distribution of the animals between time points is used to derive gross movement for the population over time. Foreground motion is calculated using an approach called difference based spatial temporal entropy image (DSTEI) (see Ma, Yu-Fei et al., In IEEE International Conference on Multimedia and Expo, 2001. ICME 2001., 265-68; the contents of which are herein incorporated by reference in its entirety). Worm morphology is measured from the worm contours detected in the images. In the process of aging, animals become shorter and stouter over time and their shape is an indicator of their overall health and biological age. The length is calculated from the central spline fitted to the worm contour and width is measured from each worm’s widest point. The animals’ posture also changes with age as they lose the ability to maintain an elongated position. Average Circularity measures how close the shape and posture come to being enclosed by a circle. Each of these measures are obtained by averaging data for all active animals detected on a plate, then averaging across different replicate plates of the same condition. All measurements are based on animals that are still alive and moving at the time of quantification. All measures are initiated animals are placed on the scanner at day 4 of adulthood.
[0168] Animals treated with the compositions of the disclosure are expected to show higher levels of activity sustained throughout the lifespan, with the higher dosage showing higher activity.
[0169] Animals treated with the compositions of the disclosure are expected to experience an increase in healthspan.
Whole transcriptome analysis
[0170] More than 150-day 1 adult animals per replicate are harvested, cleaned by filtration, and frozen at -80° in Trizol. To extract RNA, samples are thawed, vigorously vortexed, and processed using the Direct-zol RNA Miniprep Kit (Zymo Research).
[0171 ] The total RNA is enriched for poly-mRNA using oligo(dT) paramagnetic beads. DNA libraries are then constructed from this input mRNA using the NEBNext UltraTM II RNA
Library Prep Kit to create a ready-to-sequence dsDNA library that retains the strand-specific information in the original mRNA. These libraries are then further tested by the Qubit for concentration and the Agilent 2100 for library size distribution and quality. In order to properly pool the libraries and load them onto sequencing lanes to ensure the correct number of reads per sample, an even more precise quantification of the library is done via qPCR, and the samples are loaded onto the NovaSeq 6000 platform for a paired-end sequencing run of 150 bp for each end (PE150). The loading concentrations are designed to obtain at least 6.0 Gb (which is the number of billion bases of raw data, determined by the number of reads multiplied by the length of each read).
[0172] Differentially expressed genes (DEGs) are mapped to known physiological pathways and then examined for coherent linkages between pathways related to longevity. These pathways are drawn from WormBase, KEGG, and other published databases and literature. The transcriptomic analysis is expected to show that treatment with compositions of the disclosure can result in changes in expression of genes involved with insulin response, energy metabolism, and canonical longevity pathways.
Claims
1. A composition comprising glutathione, coenzyme Q10 (CoQ10), pyrroloquinoline quinone, and an iron binding glycoprotein.
2. The composition of claim 1 , wherein the concentration of glutathione is about 10 mg/ml to 100 mg/ml.
3. The composition of claim 2, wherein the concentration of glutathione is about 22 mg/ml.
4. The composition of claim 1 , wherein the concentration of CoQ10 is about 10 mg/ml to 100 mg/ml.
5. The composition of claim 4, wherein the concentration of CoQ10 is about 22 mg/ml.
6. The composition of claim 1 , wherein the concentration of pyrroloquinoline quinone is about 1 mg to 10 mg.
7. The composition of claim 6, wherein the concentration of pyrroloquinoline quinone is about 2 mg/ml.
8. The composition of claim 1 , wherein the iron binding glycoprotein is lactoferrin or transferrin.
9. The composition of claim 1 , wherein the iron binding glycoprotein is lactoferrin.
10. The composition of claim 9, wherein the lactoferrin is bovine lactoferrin.
11. The composition of claim 10, wherein the concentration of bovine lactoferrin is about 5 mg/ml to 50 mg/ml.
12. The composition of claim 11 , wherein the concentration of bovine lactoferrin is about 7 mg/ml.
13. A formulation comprising the composition of claim 1 and at least one excipient.
14. The formulation of claim 13, wherein the excipient is one or more of glycerin, medium chain triglycerides (MCT oil), oleic acid (from olive oil), natural clove oil, orange oil, cinnamon oil, vitamin E, milk, and vanilla bean extract.
15. The formulation of claim 13, comprising liposomes.
16. The formulation of claim 13, wherein a hydrophilic core of the liposomes comprises the glutathione, pyrroloquinoline quinone, and iron binding glycoprotein and the CoQ10 is associated with a hydrophobic portion of the liposomes.
17. The formulation of claim 15, wherein the liposomes comprise phosphatidylcholine.
40 The formulation of claim 15, wherein the liposomes are present within a gel. The formulation of claim 18, wherein the gel comprises at least one of a nut butter and an oil. The formulation of claim 19, wherein the nut butter is almond butter. The formulation of claim 18, wherein the oil is one or more of medium chain triglyceride (MCT) oil and sunflower oil. The formulation of claim 18, wherein the gel comprises almond butter, MCT oil, and sunflower oil. A method of treating Chronic Fatigue Syndrome (CFS) comprising administering the composition of claim 1 or the formulation of claim 13 to a subject in need thereof. The method of claim 23, wherein the composition can improve one or more symptoms associated with CFS. The method of claim 23, wherein the composition is administered for about one time, two times, three times, four times or more for 50-150 days. The method of claim 23, wherein the composition is administered for about one time, two times, three times, four times or more for 30 days. The method of claim 23, wherein the composition is administered for about one time, two times, three times, four times or more for 60 days. The method of claim 23, wherein the composition is administered for about one time, two times, three times, four times or more for 90 days. A method of increasing the healthspan or lifespan of a subject comprising administering the composition of claim 1 or the formulation of claim 13 to the subject. A method of treating a disease comprising administering the composition of claim 1 or the formulation of claim 13 to a subject in need thereof. The method of claim 30, wherein the disease is a cardiovascular disease, diabetes, a cancer, a chronic kidney disease, a chronic obstructive pulmonary disease (COPD), or a neurological disease. The method of claim 30, wherein one or more symptoms of the disease are improved by administering the composition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163264909P | 2021-12-03 | 2021-12-03 | |
US63/264,909 | 2021-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023100152A1 true WO2023100152A1 (en) | 2023-06-08 |
Family
ID=86611612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2022/061725 WO2023100152A1 (en) | 2021-12-03 | 2022-12-02 | Glutathione compositions and methods of use |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023100152A1 (en) |
-
2022
- 2022-12-02 WO PCT/IB2022/061725 patent/WO2023100152A1/en unknown
Non-Patent Citations (3)
Title |
---|
ANONYMOUS: "Liposomal Glutathione + COQ10, and PQQ", ÄLMSBIO, 1 August 2018 (2018-08-01), XP093071563, Retrieved from the Internet <URL:https://almsbio.com/products/liposomal-glutathione-coq10-pqq/> [retrieved on 20230808] * |
ANONYMOUS: "PUREDOSE® Micelle Liposomal Glutathione", PURALITY HEALTH, 7 October 2021 (2021-10-07), XP093071567, Retrieved from the Internet <URL:https://puralityhealth.com/liposomal-glutathione> [retrieved on 20230808] * |
ANONYMOUS: "What vitamins are good for muscle health", CYMBIOTIKA LLC, 17 May 2021 (2021-05-17), XP093071558, Retrieved from the Internet <URL:https://cymbiotika.ca/blogs/news/what-vitamins-are-good-for-muscle-health> [retrieved on 20230808] * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8147869B2 (en) | Liposome-encapsulated glutathione for oral administration | |
EP1406641B1 (en) | Krill extracts for prevention and/or treatment of cardiovascular diseases | |
ES2938560T3 (en) | Stable cannabinoid formulations | |
CA1339008C (en) | Amphotericin b liposome preparation | |
US5780489A (en) | Method for treating amyotrophic lateral sclerosis | |
CA2628777C (en) | Liposomal formulation for oral administration of glutathione (reduced) | |
US20140037715A1 (en) | Disulfiram formulation and uses thereof | |
JP6259474B2 (en) | Lipid nanomaterial containing lysophosphatidylcholine or derivative thereof, and method for producing the same | |
JP2001513487A (en) | Composition for treating diabetes and treatment method | |
US20150224140A1 (en) | Chromium complexes as enhancers of brain glucose transporters | |
WO2022272176A1 (en) | Psilocybin analogs for treating psychological disorders | |
WO2019159176A1 (en) | Compositions and methods for treatment of neurodegenerative diseases | |
KR102396113B1 (en) | Pharmaceutical composition for improving cognitive ability or memory | |
US20060008517A1 (en) | Treatment of age-related memory impairment | |
EP3461479B1 (en) | Nutraceutical and pharmaceutical compositions, and uses thereof for preserving cognitive functions | |
CA2877765C (en) | Liposomes comprising apoe or fragments thereof for use in the treatment of alzheimer's disease and dementia caused by .beta.-amyloid peptide | |
WO2023100152A1 (en) | Glutathione compositions and methods of use | |
JPH03501724A (en) | Liposome-introduced mepartricin | |
JP2012504164A (en) | Novel formulations for the treatment of fungal infections | |
KR20240036651A (en) | How to Inhibit the Progression of Oxidative Retinal Disease | |
JP2019511996A (en) | Compositions and methods for preventing or treating pancreatic fat infiltration and alleviating pancreatic lesions, diabetes or other related symptoms resulting from pancreatic fat infiltration | |
US8048923B2 (en) | Treatment of polyglutamine disorders caused by expanding genomic CAG nucleotides | |
EP3302432A1 (en) | Treatment of acute complications of sickle cell disease | |
JP3502951B2 (en) | Hyperlipidemia treatment | |
US20160228387A1 (en) | Solubilized formulation of coq10 for use in treatment of parkinson's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22900788 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |